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Human pluripotent stem cells (hPSCs) are a valuable resource for generating human 
cardiomyocytes and modeling human cardiac physiology in vitro. In this thesis, the 
electrophysiology of hPSC derived cardiomyocytes was studied in large populations of 
cells in syncytial models. It was found that heterogeneity in electrophysiology, as 
represented by action potential variability, is common in small clusters of hPSC-derived 
cardiomyocytes. A waveform-based automated algorithm was used to identify groups of 
cardiomyocytes based on similarity of their action potentials. It was found that, unlike in 
small cell clusters, action potential variability in monolayer culture was relatively low, 
resembling mainly a single electrophysiological phenotype. The utility of a monolayer 
hPSC-CM model was explored in two applications: 1) modeling the monogenic disease, 
type 2 Long QT syndrome (LQT2), using a human induced pluripotent stem cell (hiPSC) 
line carrying a hERG-A422T mutation, and 2) studying responses to cardioactive drugs 
using hiPSC-derived cardiomyocytes. The monolayer model with LQT2 hiPSC-derived 
cardiomyocytes had prolonged action potentials and an increased sensitivity to IKr block 
compared to that of non-disease cardiomyocytes, consistent with the expected LQT2 
 iii 
phenotype. The prolonged action potentials could be normalized by activation of IKr with 
ML-T531, a compound that delays the inactivation of the hERG channel. However, ectopic 
activity, such as early-afterdepolarizations (EADs), were mostly absent in LQT2 
monolayers, in contrast to the frequent occurrence reported in smaller cell cultures or single 
cells. For drug testing, monolayers of hiPSC-derived cardiomyocytes responded to a panel 
of eight cardioactive drugs in a manner consistent with the mechanism of the drugs: 
blockers of repolarizing currents prolonged the action potentials, while blockers of 
depolarizing currents shortened them. At a tissue level, blockers of excitatory INa slowed 
propagation of action potentials. Computational modeling showed that a drug can alter the 
repolarization gradient, a proarrhythmia biomarker, in monolayers having a defined 
electrophysiological gradient. 
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Chapter 1  
Introduction 
1.1 General overview 
The heart is the central organ in the cardiovascular system, driving blood 
throughout the circulatory system 24 hours a day, 365 days a year. Diseases in the 
cardiovascular system are the leading cause of death globally, responsible for an estimated 
17.3 million deaths in 2013 (Benjamin et al., 2017). The mechanical function of the heart 
is modulated by its electrical activities, known as cardiac electrophysiology. 
The electrical activities in the heart originate from the generation of cardiac action 
potentials within individual cardiomyocytes, which involve the coordinated operation of a 
large family of current-conducting ion channels. Action potentials then propagate 
throughout the heart, triggering mechanical contractions of the myocardium to circulate 
blood throughout the human body. Mechanistic understanding of human cardiac 
electrophysiology relies on various ex vivo and in vitro experimental models. Human heart 
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tissue excised during surgery has been used for electrophysiological studies as isolated 
muscles (Page et al., 2016; Trautwein et al., 1962), perfused wedge preparation (Boukens 
et al., 2015), organotypic slices (Kang et al., 2016), or isolated cardiomyocytes (Peeters et 
al., 1995). However, the scarce availability of human heart tissue has encouraged the 
development of alternative models, including large and small animals, isolated hearts, 
isolated cardiac tissues and cell culture models (Sigg et al., 2010). Advances in human 
genetics and molecular and cell biology also enabled the use of heterologous expression 
systems, where cardiac ion channels are expressed in non-cardiomyocytes (such as 
Xenopus oocytes, Chinese hamster ovary cells and human embryonic kidney cells), to 
study their electrophysiology (Taglialatela, 2003). 
However, differences in cross-species cardiac electrophysiology can confound the 
interpretation of findings in non-human models. Further, the lack of interactions between 
multiple ion channels limits human non-cardiomyocyte heterologous expression systems 
to investigations of single channel electrophysiology. Recently, the development of human 
pluripotent stem cells and their subsequent differentiation into cardiomyocytes has 
provided a novel platform for in vitro cardiac electrophysiology in human cardiomyocyte 
context. 
1.2 Human pluripotent stem cells and cardiac differentiation 
Human pluripotent stem cells (hPSCs) are cells that are capable of self-renewal 
and can be differentiated into descendants of all three germ layers. These cells can be 
derived from human primordial germ cells (Shamblott et al., 1998), human embryos 
(Thomson et al., 1998) or somatic cells (Takahashi et al., 2007), with the latter two being 
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most widely used, termed human embryonic stem cells (hESCs) and human induced 
pluripotent stem cells (hiPSCs), respectively. Thomson et al. was the first to derive hESC 
lines in 1998 (Thomson et al., 1998) using a similar methodology that had been developed 
for mouse ESC lines. The hESCs were derived from the inner cell mass from human 
embryos, which were donated from the result of in vitro fertilization procedures, then 
established as immortal cell lines under conditions that supported the maintenance of their 
pluripotency. The resulting cell lines could be passaged indefinitely, and are capable of 
spontaneously differentiating into all three embryonic germ layers. In 2007, one year after 
success in mouse cells, Takahashi et al. reported a new method of generating human 
pluripotent stem cells (Takahashi et al., 2007). By forced expression of four factors: Oct3/4, 
Sox2, Klf4 and c-Myc, they showed that adult cells can be reprogrammed into an 
embryonic stem cell-like state. This Nobel Prize-winning discovery completely changed 
stem cell research and many related fields. The hiPSCs derived from adult human cells 
share many key properties of their embryonic cell counterparts, including capability of self-
renewal, expression of pluripotent markers, and generation of all three germ layer cells. 
Further, the hiPSC lines preserve the genetic phenotype of their respective donors, enabling 
in vitro modeling of genetic diseases. Since then, the derivation of hiPSCs has been 
evolving rapidly. New reprogramming methods have been developed using different 
delivery vectors. More recently, vector-free methods have also been developed, aimed at 
improving the efficiency of hiPSC reprogramming as well as reducing the footprint of 
reprogramming (Malik and Rao, 2013). Despite the still relatively low reprogramming 
efficiency (generally <1%), hiPSCs are now being routinely generated in research labs 
around the world. For both hESCs and hiPSCs, the maintenance of their pluripotent state 
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in culture has also moved progressively from feeder-dependent methods (co-culture with 
mouse embryonic fibroblasts) to feeder-free, chemically defined, and xeno-free methods, 
improving the consistency of the cells and facilitating their potential clinical applications 
(Chen et al., 2011; Fan et al., 2014). 
Upon removal of factors maintaining their pluripotency, such as mouse embryonic 
fibroblast (MEF) feeder cells, and when cultured in suspension, hPSCs self-aggregate to 
form clusters, termed embryoid bodies (hEBs). These hEBs can spontaneously 
differentiate into cells from all three germ layers, including mesoderm that later gives rise 
to the heart. The monumental work by Kehat et al. demonstrated that a small percentage of 
these hEBs were spontaneously contracting and contained cells positive for cardiomyocyte 
markers, exhibiting electrogram and calcium transient activities (Kehat et al., 2001). These 
results showed that hESCs can spontaneously differentiate into human cardiomyocytes 
(hESC-CMs). The self-aggregating hEB method was later successfully applied to hiPSCs 
(Zhang et al., 2009) to generate cardiomyocytes (hiPSC-CMs). Early methods based on 
self-aggregated hEBs yielded a mixture of different cell types, including cardiomyocytes, 
and were low in efficiency, typically generating <10% cardiomyocytes. They were also 
dependent on the stem cell lines and did not transfer well across different hPSC lines. 
During the last decade, great improvement has been made to improve both the quality and 
quantity of cardiomyocytes derived from hPSCs (hPSC-CMs). By mimicking different 
stages of embryonic heart development, researchers have developed differentiation 
protocols that sequentially activate or inhibit known pathways that are involved in 
cardiogenesis, and have successfully generated cardiomyocytes at near 100% efficiency 
(Mummery et al., 2012). Overall, there are three major types of methods for cardiac 
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differentiation of hPSCs. The first type of methods is hEB-based. By utilizing tissue 
engineering approaches, such as forced aggregation (Burridge et al., 2011), microwells 
(Mohr et al., 2010) or micropatterned islands (Bauwens et al., 2008), the consistency and 
throughput of hEB-based differentiation were greatly improved compared to self-
aggregated hEBs.  The second type of methods is based on feeder-free monolayer culture 
of hPSCs, and cardiac differentiation was directly carried out in monolayer culture, 
simplifying the requirements for cell culture (Bhattacharya et al., 2014; Burridge et al., 
2015; Lian et al., 2012). The third type of methods is based on co-culture of hPSCs with 
visceral endoderm-like END2 cells, which has been shown to promote cardiogenesis 
(Mummery et al., 2003; 2007). Along with the improvement of cardiac differentiation 
efficiency, significant progress has also been made in developing scalable and robust 
production strategies for generating hPSC-derived cardiomyocytes in large quantity 
(Jenkins and Farid, 2015) with emerging commercially available products. Overall, both 
the quality and availability of hPSC-derived cardiomyocytes have greatly improved over 
the last decade, further facilitating their applications, including the study of human cardiac 
electrophysiology. 
1.3 Electrophysiology of hPSC-derived cardiomyocytes 
The first electrophysiological descriptions of hPSC-derived cardiomyocytes were 
the extracellular electrograms and intracellular Ca2+ transients generated by spontaneously 
differentiated hEBs (Kehat et al., 2001). The electrograms had a sharp component, 
corresponding to the rapid depolarization of the cardiomyocytes, followed by a relaxation 
component, corresponding to the slower repolarization. The Ca2+ transients had a rise and 
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slower decay. Both the electrograms and Ca2+ transients shared similar characteristics of 
native cardiomyocytes. Shortly afterwards, with the use of microelectrode arrays (MEAs), 
the same group demonstrated that electrical activity can spread within hEBs (Kehat et al., 
2002), suggesting the formation of a functional syncytium, another important property of 
human myocardium. These initial observations attracted significant research interest in 
exploring the electrophysiological properties of these in vitro derived human 
cardiomyocytes and their potential application as a model for electrophysiological studies. 
Action potentials are of paramount importance in cardiac electrophysiology, and 
are therefore extensively studied in hPSC-derived cardiomyocytes. Microelectrode 
recordings from both hESC- and hiPSC-derived cardiomyocytes demonstrated variable 
shapes of action potentials, roughly resembling nodal, atrial and ventricular action 
potentials found in the adult human heart (He et al., 2003; Zhang et al., 2009). These 
observations led to empirical classifications of hPSC-derived cardiomyocytes into these 
three phenotypes. However, a consistent set of quantitative criteria for phenotype 
identification has been difficult to establish (reviewed in (Blazeski et al., 2012a) and 
(Blazeski et al., 2012b)). This difficulty in classification has led to discussions on how 
action potential morphologies should be interpreted with regard to phenotype identification 
(Bett et al., 2016; Du et al., 2015; Giles and Noble, 2016; Kane et al., 2016). 
The immaturity of hPSC-derived cardiomyocytes contributes to their variable 
action potentials. At the transcriptome level, hPSC-CMs demonstrate a profile most closely 
resembling embryonic or fetal cardiomyocytes (Piccini et al., 2015; Poon et al., 2013). 
They are also morphologically smaller than adult myocytes, do not have elongated shape, 
and lack transverse tubules (T-tubules) (Yang et al., 2014). Electrophysiologically, hPSC-
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CMs generally display spontaneous activity and have more depolarized membrane 
potential at rest compared to adult cardiomyocytes (Doss et al., 2012; Ma et al., 2011). 
Functional Ca2+ stores in the sarcoplasmic reticulum (SR) and SR Ca2+-ATPase 
(SERCA)/Ryanodine receptor (RyR)-mediated calcium handling have been reported in 
hiPSC-CMs (Itzhaki et al., 2011b). Various strategies have been implemented to promote 
maturation in hPSC-derived cardiomyocytes (reviewed in (Zhu et al., 2014)), such as in-
culture electrical stimulation (Chan et al., 2013; Hirt et al., 2014), forced expression of IK1 
(Lieu et al., 2013), and electronically hyperpolarized resting potentials in hPSC-CMs (Bett 
et al., 2013). 
1.4 Ion currents associated with action potentials in hPSC-CMs 
The cardiac action potential is the change in transmembrane potential (Vm) of a 
cardiomyocyte, which is the result of organized opening and closing of current-conducting 
ion channels (Fig. 1.1, reviewed in (Baró and Escande, 2008)). In ventricular 
cardiomyocytes, an action potential begins with the activation of voltage-gated Na+ 
channels, which carry an inward current (INa) and depolarizes Vm. This depolarized Vm 
further activates several voltage-gated channels that carry both inward Ca2+ (ICaL) and 
outward K+ (Ito, IKr and IKs) currents. These currents modulate the shape of the action 
potential and regulate the mechanical contraction of a cardiomyocyte. With the progressive 
inactivation of these mid-action potential currents (ICaL, Ito, IKr and IKs) and the progressive 
activation of another K+ current (IK1), the Vm eventually returns to its resting state at a 
repolarized potential of ~80 mV, marking the end of an action potential. During the action 
potential, ion pumps and exchangers (mainly Na+/K+ pump and Na+/Ca2+ exchanger) also 
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activate to restore gradients in ion concentrations necessary for generating action 
potentials, and also carry transmembrane currents that affect Vm. 
 
Figure 1.1 Schemes of the cardiac action potential and underlying ion currents. 
Modified from (Baró and Escande, 2008)  
Action potentials in hPSC-CMs are also governed by ion currents that are found in 
human cardiomyocytes, but significant differences exist, largely associated with the 
immaturity of hPSC-CMs (reviewed in (Liu et al., 2016; van den Heuvel et al., 2014)). In 
general, the resting Vm in hPSC-CMs is more depolarized compared to adult 
cardiomyocytes, which is believed to be because of the low IK1 expression level. Forced 
overexpression of IK1, either cellularly (Lieu et al., 2013) or electronically(Bett et al., 2013) 
has been shown to improve the AP recorded in hPSC-CMs towards a more mature 
phenotype. Spontaneous activity is also generally observed in hPSC-CMs, even in those 
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characterized as having a ventricular-like phenotype. This can be explained by the 
expression of pacemaker genes in the HCN family in hPSC-CMs, which conduct the funny 
current (If) responsible for spontaneous depolarization in adult pacemaker cells, although 
a Ca2+ clock-based mechanism has also been reported (Kim et al., 2015). The major 
currents shaping the action potential (ICaL, IKr, IKs and Ito) have all been recorded in hPSC-
CMs, and these currents also respond to their respective blockers in patch clamp studies 
(Ma et al., 2011). However, the levels of currents, as well as the expression of their 
corresponding genes, are highly variable among studies (Liu et al., 2016). 
 The immature electrophysiological phenotype of hPSC-CMs is also affected by 
various in vitro factors. Extended time in culture after initiation of differentiation has been 
reported to lead to a more mature hPSC-CM phenotype, both structurally and 
electrophysiologically (Lundy et al., 2013; Robertson et al., 2013). There is also a tendency 
of hPSC-CMs shift from nodal-like to atrial/ventricular-like phenotypes with prolonged 
culture (Ben-Ari et al., 2016). Ion currents associated with APs generally increase in 
intensity with extended time in culture, including INa, ICaL, IKr， IKs and Ito, as well as pump 
current INaCa, with the important exception of IK1, which remains generally absent even 
during prolonged culture (Liu et al., 2016). The changes in electrophysiology of hPSC-
CMs are associated with physical cues that also promotes cardiomyocyte maturation during 
heart development. For example, chronic electrical pacing has been shown to improve the 
maturity of hESC-CMs in terms of reduced spontaneous activity, more hyperpolarized 
resting potential and increased AP-associated ion channel expression (Chan et al., 2013; 
Lieu et al., 2013). Further, mechanical stimulation and three-dimensional culture methods 
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have also been shown to improve the maturity in the electrophysiology of hPSC-CMs (Zhu 
et al., 2014). 
1.5 Disease modeling with human induced pluripotent stem cells 
Congenital heart diseases are abnormalities in the function of the heart as a result 
of genetic disorders. It affects more than 9 per 1000 live births worldwide and is one of the 
major congenital anomalies (van der Linde et al., 2011). Mechanistic understanding of 
disease pathogenesis, phenotype and treatment evaluation requires development of in vitro 
disease models. While a limited repository of hESC lines with genetic disorders has been 
reported (Verlinsky et al., 2005), and mutant hESC lines could be created by genetic 
modification (Bellin et al., 2013), in practice working with hESC diseased models is very 
difficult and of limited application due to limited availability of the cell lines and complex 
procedure of genetic modification. The development of human iPSC-derived 
cardiomyocytes has provided an exciting platform for mechanistically studying inherited 
cardiac diseases, since iPSCs can be derived directly from patient somatic cells, preserving 
the patient-specific genotype in subsequent differentiation into cardiomyocytes. It has 
promising applications in both monogenic and multifactorial genetic disorders. The first 
hiPSC disease model was developed from patients with a familial form of amyotrophic 
lateral sclerosis (ALS), and the authors demonstrated that disease-relevant cells, in this 
case motor neurons, could be differentiated from the patient-specific hiPSCs (Dimos et al., 
2008). In the cardiac field, Carvajal-Vergara et al. was first to report a disease model with 
cardiac consequences -- the multisystem genetic disorder known as LEOPARD syndrome 
(Carvajal-Vergara et al., 2010). It was found that cardiomyocytes differentiated from 
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patient-derived iPSCs had phenotypic characteristics resembling a hypertrophic state, 
which is a condition common in LEOPARD syndrome patients. The in vitro recapitulation 
of a disease phenotype in hiPSC-CMs demonstrated the promise of patient-derived iPSCs 
for cardiac disease modeling, and led to the development of many hiPSC-based cardiac 
disease models (Shaheen et al., 2017).  
The major congenital heart diseases that have been studied in hiPSC-derived 
cardiomyocyte models include cardiac channelopathies and cardiomyopathies (Matsa et al., 
2014). In cardiac channelopathies, mutations in cardiac ion channels lead to abnormalities 
in cardiac electrophysiology and arrhythmia. This mainly includes long-QT syndrome 
(LQTS) (Moretti et al., 2010) and catecholaminergic polymorphic ventricular tachycardia 
(CPVT) (Novak et al., 2012). In cardiomyopathies, genetic mutations lead to myocardial 
dysfunction such as dilated cardiomyopathy (DCM) (Sun et al., 2012), hypertrophic 
cardiomyopathy (HCM) (Lan et al., 2013) and arrhythmogenic right ventricular 
cardiomyopathy (ARVC) (Kim et al., 2013). 
The most extensive family of diseases that has been modeled with hiPSC-derived 
cardiomyocytes is long-QT syndrome, as this is often the result of a single gene mutation 
(Tester and Ackerman, 2014). Electrophysiological consequences of LQTS include 
prolonged QT interval and increased risk of developing a specific type of polymorphic 
ventricular tachycardia known as Torsades de Pointes (TdP). Three genes that account for 
the majority of LQTS are KCNQ1, KCNH2 and SCN5A, encoding the alpha subunits of the 
cardiac ion channels: IKs, IKr and INa, respectively. Multiple mutations have been identified 
within each gene to be responsible for LQTS and have been modeled with hiPSC-derived 
cardiomyocytes (reviewed in (Blazeski et al., 2012b; Shaheen et al., 2017; Yang et al., 
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2015)). Electrophysiological consequences of LQTS mutations are widely studied by using 
patch clamp or MEAs in cardiomyocytes derived from patient-specific hiPSCs. These 
cardiomyocytes have been found to have prolonged action potentials and increased 
occurrence of ectopic activity such as early afterdepolarizations (EADs) (Itzhaki et al., 
2011a; Lahti et al., 2012; Matsa et al., 2011; Moretti et al., 2010), which reflect the 
corresponding abnormal function in ion channels specific to the mutations. Patient-specific 
hiPSC-CMs also provide a valuable platform to evaluate rescue strategies for LQTS. Some 
examples include modulation of the hERG channel to compensate for loss of function in 
IKs in an LQT1 model (Zhang et al., 2012), pharmacological rescue of a trafficking defect 
in an LQT2 model (Mehta et al., 2014a) and most recently, genome editing in an LQT15 
model (Yamamoto et al., 2017). 
1.6 Drug-induced proarrhythmia testing 
To successfully bring a lead compound found in drug discovery to the market, it 
must go through a thorough process of preclinical and clinical evaluations before obtaining 
approval from the regulatory agency. Once on the market, all drugs are still constantly 
monitored for potential adverse effects and are subject to withdrawal if adverse effects do 
arise. This is a process that associates with a cost of hundreds of millions of dollars per 
drug (DiMasi et al., 2003). Regardless of whether the drug in development is intended for 
treating cardiac disease, cardiac safety is among the top reasons for the termination of drug 
development or even withdrawal of drugs already in the market (Fung et al., 2001). The 
main concerns of cardiac safety are direct cardiomyocyte toxicity which leads to 
myocardial cell necrosis, and proarrhythmia which leads to increased risk of sudden and 
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life-threatening arrhythmic events. While effective biomarkers such as serum cardiac 
troponin has been identified for early detection of cardiomyocyte toxicity (Gaze and 
Collinson, 2005), the evaluation of drug-induced proarrhythmia has proven to be more 
difficult, especially in finding a preclinical biomarker or assay that can accurately predict 
the rare, but potentially lethal, occurrence of drug-induced arrhythmia in clinical use. 
The most common drug-induced arrhythmia is TdP, a type of polymorphic 
ventricular tachycardia which has a distinct appearance in the electrocardiogram (ECG) 
and can degenerate into life-threatening ventricular fibrillation. TdP is well acknowledged 
to be associated with the prolongation of the QT interval in the ECG (in congenital or 
acquired LQTS). More than a decade ago, Redfern et al. performed a thorough 
investigation of the relationships between QT prolongation, occurrence of TdP and 
preclinical biomarkers for 100 drugs, and concluded that blockade of hERG is associated 
with most TdP-associated drugs (Redfern et al., 2003). The strong correlation between 
hERG blockade, QT prolongation and TdP facilitated the development of the preclinical 
hERG-based assay and the clinical thorough QT study (TQT) and eventually led to the 
establishment of two International Conference on Harmonization (ICH) guidelines: S7B 
on non-clinical evaluation and E14 on clinical evaluation of QT prolongation and drug 
proarrhythmia. The interactions between a lead compound and the hERG channel can be 
tested by several different assays, ranging from high throughput non-functional binding 
assays, to medium throughput flux- or fluorescence-based assays, to low throughput 
manual or automatic patch clamp assays (Priest et al., 2008). These assays have been used 
in different phases of drug development. 
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The electrophysiological basis of hERG-based assays lies in the role of IKr in the 
cardiac action potential. IKr, the rapid component of the delayed outward rectifying current, 
is a repolarizing current that is conducted through a potassium ion channel with hERG 
encoding its alpha subunit. Blockade of IKr leads to a delay in repolarization and increase 
in duration of the action potential, which manifests as a prolonged QT interval in the ECG. 
However, cardiac action potentials are the result of delicately balanced ion currents. IKr is 
not the only current determining action potential duration and QT interval. Interactions of 
the drug with multiple ion channels can either augment or weaken the effect of the drug on 
the action potential beyond the effect on hERG alone.  
A delay in repolarization or QT prolongation per se is proarrhythmic because it can 
favor the formation of EADs and ectopic activity in the heart. However, a heterogeneous 
substrate, which favors wavefront curvature and conduction block, could lead to reentrant 
arrhythmia under certain conditions (Boukens et al., 2016). For these two reasons, along 
with others, it is apparent that the hERG assay may be inadequate as a biomarker for drug-
induced proarrhythmia. In fact, there are drugs that block hERG current but do not prolong 
QT interval, such as fluoxetine and verapamil (Gintant et al., 2006), and drugs that prolong 
QT interval through hERG blockade, but are extremely low in risk of proarrhythmia, such 
as amiodarone, quetiapine, phenobarbital and ranolazine (Piccini et al., 2009). Overall, the 
performance of the hERG-based assay in determining drug-induced proarrhythmia is 
limited, and therefore new strategies for drug discovery are warranted (Gintant, 2011). 
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1.7 Overview of thesis 
Human PSC-derived cardiomyocytes present an exciting tool for in vitro studies of 
human cardiac electrophysiology. The goal of this thesis is to explore the utility of hPSC-
CMs in a syncytial context, where large populations of cells can interact and exhibit 
coordinated electrical activity, much like the native myocardium. In Chapter 2, 
electrophysiological characteristics of hPSC-CMs are compared between a small cell 
cluster and a large syncytial cell monolayer, especially in terms of the variability in action 
potentials. This comparison provides a baseline characterization of hPSC-CM 
electrophysiology in cell monolayers. In Chapter 3, a disease model with a syncytial 
monolayer is studied by using cardiomyocytes carrying a mutation that leads to type 2 
LQTS, and a potential pharmacological rescuing strategy is evaluated. In Chapter 4, the 
syncytial monolayer model is applied to test the response of hiPSC-CMs to cardioactive 
drugs, and how such monolayer models can provide insight into drug-induced 
proarrhythmia is discussed. I conclude in Chapter 5 by discussing the implication and 
limitations of the current study and potential future directions for electrophysiological 




Chapter 2  
Electrophysiology and variability in human PSC-
CMs 
2.1 Introduction 
Cardiomyocytes derived from human pluripotent stem cells are a novel platform 
for the in vitro study of cardiac physiology. The self-renewal capability of hPSCs allows 
virtually unlimited access to precious human cardiomyocytes. Further, cardiomyocytes 
derived from hiPSCs carry the same genotype as their donor, enabling in vitro disease 
models to be developed. However, our understanding of hPSC derived cardiomyocytes is 
far from comprehensive, making it difficult to interpret findings in hPSC-CMs.  
Cardiac electrophysiology is the physiology of the electrical activity in 
cardiomyocytes, which involves the coordinated operation of cardiac ion channels that 
carry electrical currents across the cell membrane. At the cellular level, this generates 
action potentials, where cardiomyocytes go through phases of depolarization, plateau, 
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repolarization and rest. This highly organized sequence of events initiates and regulates the 
mechanical contractile function of cardiomyocytes, which fulfills the heart’s function to 
pump blood throughout the circulatory system.  
The balanced interaction of ion channels that governs cardiac action potentials is 
subject to biological variability. In the native heart, this variability manifests mainly in two 
ways. First, cardiomyocytes located in different regions of the heart have different 
electrophysiology adapted to their specialized role. For example, cardiomyocytes in the 
sinoatrial node have a spontaneous depolarizing resting phase because of If expression. The 
rate of this spontaneous depolarization sets the heart rate. On the other hand, 
cardiomyocytes in the ventricles are characterized by having a prominent plateau phase, 
where the membrane potential stays relatively close to 0 mV for an extended period, 
allowing calcium to enter the cell and facilitating electrical-contraction interactions that are 
key in the process known as excitation-contraction coupling. These major phenotypic 
differences in cardiomyocyte electrophysiology are the result of different functional 
specializations within the heart and are developed based on the major anatomical structures 
such as the four chambers and the conduction system within the heart (Baró and Escande, 
2008). Second, in addition to the major phenotypes, there are subtle differences in 
electrophysiology of cardiomyocytes within the same phenotype, such as the transmural 
heterogeneity across the ventricular wall, where cardiomyocytes from the endocardium and 
epicardium have slight differences in action potential shape and duration. These subtle 
differences compensate for the non-simultaneous ventricular activation and is essential for 
healthy cardiac function. However, when the heterogeneity become excessive it can also 
lead to arrhythmia (Boukens et al., 2016). 
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Cardiomyocytes derived from hPSCs recapitulate many important properties of the 
native human cardiomyocyte in terms of their electrophysiology and cell and molecular 
biology. Action potentials recorded from hPSC-CMs have shown that they resemble those 
of all three major phenotypes of native cardiomyocytes. However, the criteria for assigning 
electrophysiological phenotypes are inconsistent among research groups. Attempts have 
also been made to study the electrophysiology of hPSC-derived cardiomyocytes in large 
populations of cells (López-Redondo et al., 2016), but due to the low throughput patch-
clamp procedure, this has been greatly limited to only 93 samples. 
In this chapter, I investigate the electrophysiology of hPSC-derived cardiomyocytes 
obtained from two different cardiac differentiation methods. The first one is an hEB-based 
method, which generates independent aggregates of cells containing cardiomyocytes. In 
this model, the electrophysiology of cardiomyocyte populations is analyzed both across 
hEBs and within each hEB. The second differentiation method is monolayer-based, which 
generates cardiomyocytes in a much larger, tissue-like context and enables measurement 
of tissue-level properties such as conduction which is very difficult with small clusters. By 
using high-resolution optical mapping, I study action potentials recorded simultaneously 
from hundreds to thousands of sites within a single preparation. The work on hEBs in this 
chapter has been published (Zhu et al., 2016). 
2.2 Methods 
2.2.1 Human PSC culture and cardiac differentiation 
For hEB-based cardiac differentiation, the H9 line of hESCs (WiCell WA09) was 
used. H9 hESCs were maintained on a layer of MEF feeder cells and dissociated to form 
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hEBs just before initiation of differentiation. Spontaneous beating hEBs were obtained 
using a forced aggregation method with 5×103 cells initially seeded per aggregate 
(Burridge et al., 2011; Burridge and Zambidis, 2013). Beating areas of hEBs from the same 
differentiation batch were mechanically dissected on day 15 of differentiation, and then 
transferred to plastic coverslips coated with 0.1% gelatin (Sigma-Aldrich).  These cardiac 
cell clusters were maintained in culture for at least 5 days to attach and recover before 
optical mapping experiments were conducted at 21-24 days after initiation of 
differentiation. 
For monolayer-based cardiac differentiation, the WT11 line of hiPSCs (a kind gift 
from Dr. Bruce Conklin, UCSF) was maintained in feeder-free monolayer culture in 
Essential 8 medium (ThermoFisher) and differentiated into cardiomyocytes using a 
monolayer-based protocol (Boheler et al., 2014; Wang et al., 2015). Beating monolayers 
were dissociated with 0.05% Trypsin (ThermoFisher) and re-plated on Geltrex (Gibco)-
coated cell culture plates between 15 and 20 days after initiation of differentiation. A 
second dissociation was performed 5-7 days afterwards, after which the beating 
cardiomyocytes were seeded at 3×105 cells/cm2 density onto a Geltrex-coated 35 mm 
diameter tissue culture dish. The growth area of the tissue culture dish was restricted to a 
10 mm diameter circle by using a polydimethylsiloxane (PDMS) stencil: PDMS was filled 
and heat-cured in 35 mm diameter tissue culture dishes to completely block the cell culture-
treated surface, after which a 10 mm diameter core of PDMS was removed by a dermal 
punch, exposing the cell culture-treated surface underneath. This exposed surface was then 
coated with Geltrex. The use of the PDMS stencil created a defined size and shape of the 
monolayer, which was matched to the field of view of the optical mapping system. The 
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monolayers were kept in culture for 35-55 days total after initiation of differentiation before 
proceeding further with experiments. A small percentage of monolayers that detached from 
the culture vessel during this time were excluded from experiments. 
Commercially available Cor.4U hiPSC-CMs were obtained as frozen vials (Lot 
CB142CL_V_4M) from Axiogenesis along with manufacturer-provided culture media. 
Cells were thawed into fibronectin-coated T75 tissue culture flasks per the manufacturer’s 
protocol and kept for 2 days for recovery. Cells were then dissociated and re-plated onto 
fibronectin-coated 35 mm dishes at 1.6×105 cells/cm2 to form confluent cell monolayers. 
The growth area was also restricted to a 10 mm diameter circle by a PDMS stencil. The 
monolayers were cultured for an additional 7 to 8 days per the manufacturer’s 
recommendation before optical mapping experiments began. 
2.2.2 Optical mapping 
Optical recordings of action potentials were performed using epifluorescence 
imaging. Both hEBs and monolayers were stained with 10 µM di-4-ANEPPS 
(ThermoFisher), a voltage-sensitive dye, for 10 min to enable optical recordings of 
electrical activity. The samples were kept in Tyrode’s solution (135 mM NaCl, 5.4 m M 
KCl, 1.8 mM CaCl2, 1.0 mM MgCl2, 0.33 mM NaH2PO4, 5.0 mM HEPES and 5.0 mM 
glucose, all from Sigma-Aldrich) warmed to 37°C throughout the experiments. To inhibit 
motion, blebbistatin (Sigma-Aldrich), a myosin II inhibitor, was added to the Tyrode’s 
solution at 50 µM for hEB experiments and at 10 µM for monolayer experiments. For 
experiments with applied cardioactive compounds, including E-4031 and carbenoxolone 
(both from Tocris), each compound was prepared as a stock solution that was 1000× the 
concentration of the lowest concentration tested in dimethyl sulfoxide (for E-4031) or 
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water (for carbenoxolone). The stock solution of the volume equal to 1/1000 of the volume 
of Tyrode’s solution in the mapping chamber was added during optical mapping to yield 
the desired test concentration. When multiple concentrations were tested, the higher 
concentrations were achieved by serially adding the differential amount of necessary stock 
solution into the mapping chamber containing Tyrode’s solution. 
Electrical pacing was delivered through a pair of platinum electrodes. For hEB 
experiments, electrodes were placed across hEBs, delivering field pacing as 5-10 ms 
rectangular voltage pulses. Pacing rate started at 60 beats per minute (bpm), and was 
incremented in steps of 30 bpm until the cluster failed to maintain 1:1 capture by the pacing 
stimulus. For monolayer experiments, point pacing was delivered at the edge of the 
monolayer to initiate propagating action potentials across the monolayer. A cycle length of 
1000 ms, equivalent to 60 bpm, was used for monolayer experiments. 
Optical action potentials were recorded using a MiCAM Ultima-L CMOS camera 
with 100 × 100 pixels at 500 frames per second (fps). The schematic of the optical mapping 
system is shown in Fig. 2.1A, and a photograph of the mapping setup with details of the 
objectivelens, pacing electrode, sample and heated stage is shown in Fig. 2.1B. A tandem 
combination of a 5x objective and 0.63x condensing lens was used for hEB experiments, 
resulting a 1.6 mm-by-1.6 mm field of view (16 µm/pixel). A tandem combination of a 1x 
objective and 1x condensing lens was used for monolayer experiments, resulting a 1cm-
by-1cm field of view (100 µm/pixel). 
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Figure 2.1 The optical mapping system. (A) Schematic drawing of the optical mapping 
system. The excitation light (Lamp, 2 × 150W halogen lamps) is filtered through an 
excitation filter (Ex, 531/40 nm bandpass) and reflected by the dichroic mirror (D, 560 
nm), through the objective lens (L1, switchable various magnifications) onto the Sample 
sitting on a Heated stage. The emission light is collected through L1, and the component 
longer than 560 nm passes through D, filtered by the emission filter (Em, 610 nm longpass) 
and projected through the condensing lens (L2, switchable various magnifications) onto 
the CMOS sensor in the Camera. Pacing electrode is held by an electrode holder with the 
tip of the electrodes placed next to the Sample. (B) Photograph of the mapping system 
highlighting L1, Pacing electrode, Sample and Heated stage. 
2.2.3 Signal processing and data analysis 
For hEBs, the optical action potential recordings were convolved with a 5×5 boxcar 
filter to improve signal quality. The border of each cluster was traced manually to identify 
the recording pixels contained within that cluster. When electrical pacing was applied, 
multiple APs from each recording site were temporally aligned by their activation times 
(calculated as the time of fastest AP upstroke), after which an average of the APs was 
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calculated for that recording site. The averaged APs were quantified by 4 parameters: AP 
duration at 30% and 80% repolarization (APD30 and APD80, respectively), triangulation 
(time from APD30 to APD80) and fractional repolarization time (time from APD30 to APD80 
divided by APD80). For triangulation, APD80, rather than APD90 as originally defined by 
Hondeghem et al., (Hondeghem et al., 2001) was used because in some cells the AP had a 
slow repolarizing tail following the rapid repolarization phase, making measurements of 
the time of 90% repolarization difficult. These four parameters were used to quantify AP 
variability within and among clusters. Principal component analysis (Abdi and Williams, 
2010) was used to determine the linear combination of AP parameters that accounted for 
the most variability within the dataset by orthogonal transformation. Levene’s test of equal 
variances was used to compare the variability in APD80 at spontaneous or paced conditions. 
For monolayers, optical action potential recordings were convolved with a 5×5 
Gaussian filter to improve signal quality. The portion of the camera image that 
corresponded to the monolayer was identified by including pixels whose optical signal 
contained a primary frequency component equal to the frequency of applied electrical 
pacing. Both APD30 and APD80 were calculated as defined for hEB experiments, and the 
interquartile range of APD80 (IQR-APD80), the range between the 25
th and 75th percentile 
of APD80, was used to quantify action potential variability in the monolayers. 
2.2.4 Automated grouping 
For hEB experiments, action potentials recorded from clusters paced at 90 bpm 
were separated into groups based on their action potential morphology, using a waveform-
based automated algorithm previously described (Gorospe et al., 2014). This grouping 
algorithm had been developed using data from 9 of the 32 clusters presented here. Briefly, 
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APs were divided into 2 or 3 groups based on an unsupervised, spectral clustering 
technique that amasses APs with similar shapes together and separates APs having 
different shapes. The similarity between pairs of APs is calculated mathematically as a 
weighted function based on the cumulative squared errors between the two temporal 
waveforms. Davies-Bouldin Index (DBI) (Davies and Bouldin, 1979) was also calculated 
using the cumulative squared errors, to compare cluster separation for different numbers 
of groups. Linear decision boundaries in pairs of AP parameter spaces were derived by 
support vector machines (SVMs) using labels determined by the spectral clustering. 
2.2.5 Statistics 
Data are presented as mean±SD, with n values provided. Levene’s test of equal 
variances was used to compare the variability in APD80 at spontaneous or paced conditions. 
The paired Student’s t-test was used to compare IQR-APD80 and conduction velocities 
before and after drug applications, where a significance level of p < 0.05 was used. 
2.3 Results 
2.3.1 Action potential variability in hESC-CM clusters 
Spontaneous and electrically stimulated activity of cardiac cell clusters 
Spontaneously beating hEBs started to emerge in culture around day 10 of 
differentiation. The number of beating hEBs varied as differentiation proceeded and varied 
among differentiation batches. To minimize inter-batch variability, hEBs from a single 
batch of differentiation were used, where more than 90% of hEBs were beating by day 15 
(day of mechanical dissection). Although similar numbers of undifferentiated hESCs were 
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seeded for hEB formation (5×103 cells/hEB), clear differences in size and shape of hEBs 
and their beating areas were observed (Fig. 2.2A, left column). After mechanical 
dissection, all cardiac cell clusters (beating areas of hEBs) attached to the coverslip and 
recovered spontaneous beating within 5 days, prior to being optically mapped. 
From the 55 clusters obtained from this batch, spontaneous APs were recorded 
using optical mapping. Both continuous (35 clusters) and episodic (20 clusters) patterns of 
beating were observed, the latter being identified by the existence of at least 4 seconds of 
quiescence between APs during the recording. Among continuously beating clusters, 
beating rate was unstable in 6 clusters. Action potentials recorded from different clusters 
exhibited different spontaneous rates and had clearly different morphologies (Fig. 2.2A, 
middle column). The average beating rate of stable, continuously beating clusters was 
62±21 bpm (mean±SD), and their average APD80 was 165±49 ms (n=29). Because action 
potential characteristics and their underlying ion currents are known to be rate-dependent, 
a test of whether some of the variability in APD80 of the clusters could be secondary to the 
differences in the beat rates was performed. Thus, electrical pacing was applied as 
described in 2.2.2. In the examples shown, a fixed rate of 90 bpm was able to pace-capture, 
and reduced, but did not eliminate the differences among APs from different clusters (Fig. 
2.2A, right column). 
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Figure 2.2 Spontaneous activity of cardiac cell clusters. (A) Left column: three beating 
hEBs at 14 days after initiating cardiac differentiation. Dashed contours indicate beating 
areas. Middle column: spontaneous action potentials recorded from a site in each of the 
cardiac cell clusters derived from the three hEBs. Right column: action potentials recorded 
from the same sites of each cluster during 90 bpm pacing. (B) APD80 of spontaneous and 
paced cardiac cell clusters. Open circles: APD80 of spontaneous APs recorded from 14 
cardiac cell clusters. Closed circles: APD80 of APs recorded at fixed 90 bpm pacing rate. 
Dashed line connecting open and closed circles indicates the same cluster. 
Overall, 14 of the 29 continuously beating clusters with stable beating rate could 
be entrained by electrical stimulation at 90 bpm. For these 14 clusters, individual APD80s 
measured during spontaneous beating did not correlate with the beat rate (Fig. 2.2B, open 
circles), and different APD80s were observed even among clusters with similar beat rate. 
When 90 bpm pacing was applied, there was no significant change in the mean or SD of 
APD80 (147±36 (mean±SD) ms without pacing compared with 143±33 ms with pacing, 
Fig. 2.2B, closed circles). In most cases, the increase in beating rate from spontaneous rate 
to 90 bpm produced a drop in APD80, consistent with the negative rate-dependence 
observed in natural human cardiomyocytes/tissue, although it was the opposite case for 4 
of the 14 clusters where APD80 increased instead. The large variability in APD80 at 90 bpm 
and the distinctly different rate-dependences among clusters indicate that both rate-
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independent and rate-dependent effects contribute to the variable AP durations observed at 
spontaneous beat rates. 
Variability of APs within cardiac cell clusters 
The rate-independent variability of APs within cardiac cell clusters was first studied 
by pacing the clusters at a common rate of 90 bpm, and then recording the spatial 
distribution of action potentials via high-resolution optical mapping. A representative 
example is shown in Fig. 2.3A, where APD80 of 981 recordings obtained from a single 
cluster are shown as a histogram. The average APD80 was 119±19 ms, and two prominent 
distribution peaks were observed in the histogram, suggesting the existence of two 
subpopulations within the cluster. The advantage of optical mapping is its ability to 
discriminate whether the two subpopulations are interspersed or whether they cluster 
together spatially. In the spatial map of this cluster (Fig. 2.3B), two distinct regions having 
either long or short APD80 were apparent, indicating that on a local scale of the order of a 
hundred microns, cells have similar AP duration, but on a larger scale of the order of a mm, 
different AP durations can emerge. 
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Figure 2.3 Variability of action potentials within a single cardiac cell cluster and 
among different clusters. (A) APD80 histogram of action potentials recorded from a 
cardiac cell cluster (cluster 9). Two peaks in the histogram indicate subpopulations with 
predominantly long or short durations. (B) Sample action potentials recorded from this 
cluster. Center: APD80 map, showing two distinct regions with long or short AP durations. 
(C-F) Single AP parameter histograms (APD80, APD30, triangulation and fractional 
repolarization; see main text for definition) of 32 cardiac cell clusters paced at 90 bpm. 
Each row represents one cluster. The overall distribution (bottom row) is the summation of 
all recording sites (n=23117) from these 32 clusters. 
Next, AP variability within each cardiac cell cluster was compared to that among 
the entire cluster population. Fixed 90 bpm recordings were obtained from 32 cardiac cell 
clusters with an average of 722±252 recording sites in each cluster. The average and 
variation in AP parameters are summarized in Table 2.1. Even though some of these 
clusters had spontaneous activity (including the 14 continuously beating clusters analyzed 
in Fig. 2.2) while others were quiescent, there were no systematic differences in APs when 
they were paced at 90 bpm that could be correlated to their spontaneous rates. Single AP 
parameter distributions for individual clusters were clearly different (Fig. 2.3 C-F). In some 
clusters (e.g, clusters 4, 24, 25, 28), the distributions of all AP parameters were relatively 
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narrow, indicating a relatively homogeneous population of cells within the cluster, whereas 
in other clusters (e.g. clusters 8, 21, 27, 30) AP parameters were distributed over a wide 
range and had multiple peaks, revealing multiple sub-populations or a spectrum of cells. In 
other clusters (e.g. cluster 7), while distributions for some AP parameters (APD80, APD30 
and fractional repolarization) were relatively narrow, much wider distributions were found 
in triangulation. Thus, AP variability presents differently for different AP parameters. 
Therefore differences in subpopulation identification may be expected when a single AP 
parameter (such as APD80) is used compared to when multiple AP parameters, or the entire 
AP waveform is used. 
Table 2.1 Variability of AP parameters within individual and among all 32 clusters 
paced at 90 bpm 





46 to 188 ms 85 to 257 ms 45 to 117 ms 0.27 to 0.51 
Overall Mean 85 ms 137 ms 70 ms 0.41 
Individual SDs 4.3 to 30 ms 6.5 to 34 ms 4.8 to 58 ms 0.03 to 0.11 
Overall SD 33 ms 41 ms 24 ms 0.09 
 
To further investigate the potential subpopulations among these cardiac cell 
clusters, different grouping strategies were applied to the dataset and compared against 
each other. Starting with APD80, two Gaussian distributions were fitted to the overall 
distribution of the entire population, and the crossover value was used as a threshold that 
divided APs into two groups, namely groups of long or short AP, respectively (Fig. 2.4A). 
The average action potentials from the two groups are shown in Fig. 2.4D. Another action 
potential parameter, APD30 was then added to the analysis. Using principal component 
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(PC) analysis, the linear combination of APD80 and APD30 that accounted for most of the 
variability in the population was identified, and its distribution is shown in Fig. 2.4B. By 
fitting two Gaussian distributions and using the crossover value, the APs were again 
divided into two groups, and the average AP from each group is shown in Fig. 2.4E. In a 
third approach, an automated unsupervised algorithm was used to provide an unbiased 
grouping of APs based on their wave shapes across the entire cluster population. Fig. 2.4C 
shows the grouping results displayed in terms of APD80 and color-coded by the group 
assignment. Only a small fraction of the action potentials (in light blue) were labeled as 
different from the bulk of the population, leading to a very different result than those using 
AP parameters alone (Fig. 2.4A and 2.4B). The average APs from the two groups identified 
by waveform analysis are shown in Fig. 2.4F. Compared with the average APs using AP 
parameter analysis (Fig. 2.4D and 2.4E), these had greater differences in morphology (Fig. 
2.4F), with one group having a shorter AP with more triangular profile, and the other group 
having a longer AP and a longer plateau phase. Differences among the three grouping 
methods can be visualized in the joint distribution of measured APD30 and APD80 (Fig. 
2.4G). Here, dashed lines have been drawn corresponding to decision boundaries between 
the two groups determined by the analysis of: (1) APD80 only, (2) APD80 + APD30 PC, and 
(3) entire waveform. While the APD80-only method always grouped cells with similar 
APD80 values together, the variability in their APD30 (as indicated by the vertical spread in 
the joint distribution) resulted in AP groups that could include very different AP shapes. 
The inclusion of APD30 introduced a tilt to the threshold line (compare lines 1 and 2), 
indicating the contribution of both parameters to the subtype identification. To quantify the 
distinction between groups, the Davies-Bouldin Index (Fig. 2.4H) was calculated, which 
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compares within-group tightness against between-group separations, such that lower DBI 
indicates better clustering (tighter groups and/or larger separations). DBI was lower for 
groups identified by waveform analysis (0.75) than when groups were identified by APD80-
threshold (0.93) or PCA (0.93) (Fig. 2.4H).  
 
Figure 2.4 Comparison of grouping methods. (A) Histogram of APD80 from all 
recording sites from 32 clusters. Solid lines show fits of the data by two Gaussian curves, 
and dashed line indicates threshold used to divide groups of APs (shown in brown and 
blue). (B) Histogram of the principal component (PC), which is a linear combination of 
APD80 and APD30. Solid lines show fits of the PC data by two Gaussian distributions, and 
dashed line indicates threshold used to divide groups of APs (shown in brown and blue). 
(C) Histogram of APD80 with waveform-based grouping, with colors showing different 
groups. Stacking of different colors indicate overlap in APD80 parameters between groups. 
(D-F) Average AP traces obtained by grouping APs based on APD80 threshold, PC of 
APD30 and APD80, and waveform analysis, respectively. (G) Scatter plot of APD80 and 
APD30 for all recorded APs. Dashed lines represent linear classification boundaries 
according to (1) threshold using APD80, (2) threshold using the principal component, which 
is a linear combination of APD30 and APD80 and (3) waveform analysis. (H) Comparison 
of APD80 between groups for the three different grouping methods. Colored bars 
correspond to groups of APs shown in (A-C). Waveform analysis resulted in groups with 
the most distinct AP differences, as indicated by the lowest DBI value. 
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Differences in the outcomes of the parameter and waveform analyses are especially 
apparent in comparing APs within individual clusters (e.g, clusters 7 and 27 in Fig. 2.5). 
APD80 maps (Fig. 2.5A) showed considerable variability between the two clusters, 
reflecting differences among the AP waveforms (Fig. 2.5B). Among the 4 APs shown, one 
had short duration with rapid repolarization (a), one had a short duration with a slow 
repolarization tail at the end of the AP (b), one was very triangular (c) and the last had a 
long duration with rapid repolarization (d). Different groupings were obtained with the 
single parameter analysis (here, being APD80) compared with the waveform analysis. 
APD80 analysis grouped APs b and c with AP d, whereas waveform analysis grouped these 
APs with AP a. The limitations of single parameter analysis are also illustrated for APs 
having the same APD80 (Fig. 2.5C) but drastically different morphology. Analysis in terms 
of other parameters (such as APD30 in Fig. 2.5D) also encounter morphological differences. 
Only when both APD80 and APD30 were used together, were the morphological differences 
greatly reduced (Fig. 2.5E). Waveform analysis was successful in separating these APs into 
different groups. Furthermore, the slower repolarization and more triangulated shapes in 
APs b-c could be captured by analyzing all of the APs as 3 groups, whereupon APs b-c 
were identified as belonging to the third group.  
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Figure 2.5 Comparison between grouping by single AP parameter (APD80) and by 
waveform analysis. (A) APD80 map of two clusters. (B) APs recorded from locations 
indicated by black dots in (A), showing significant differences in AP morphology. 
Grouping results using different methods are shown as color-coded bars below. APs having 
the same APD80 (C) or APD30 (D) can have very different morphology. (E) APs having 
both same APD80 and APD30 have similar shapes. 
The analysis of spatial heterogeneity was then expanded to two other metrics of AP 
shape: triangulation and fractional repolarization. Five representative clusters are shown in 
Fig. 2.6 (rows 1-4 for 4 total AP parameters, one cluster per column). In some cases (cluster 
4), APD30, APD80, fractional repolarization and triangulation were uniform across the 
cluster, indicating a single population of cells. In other cases (clusters 9, 27) the 4 AP 
parameters had similar patterns showing two distinct regions (e.g, on the left and right sides 
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of cluster 9, and lower left and upper right sides of cluster 27) indicative of two 
subpopulations, although for cluster 27 the regions were not entirely concordant across 
parameters. In still other cases (cluster 7, 24) the patterns for the AP parameters were 
dissimilar. By using the automated algorithm with the entire AP waveform, cells among 
the clusters were separated into 2 groups, with spatial patterns as shown (Fig. 2.6, second 
to last row). The 2-group analysis revealed that 14 of 32 clusters contained cells from 
different groups. This coexistence of cells from different groups is more notable with 
automated 3-group analysis (Fig. 2.6, last row), where 17 clusters had cells from all 3 
groups, 12 clusters had cells from 2 different groups, and only 3 clusters had cells from a 
single (and different) group. Furthermore, cells belonging to different groups were not 
intermingled and tended to occupy separate areas within a cluster (Fig. 2.6, last two rows) 
even though spatial information was not incorporated into the grouping algorithm. Separate 
groups could be identified even in clusters where the patterns of APD parameters were 
discordant (e.g. cluster 24). Additionally, the analysis described in this chapter resulted in 
the identification of individual AP phenotypes that were common to multiple clusters (e.g., 
group 3 in clusters 9, 24, and 27). Note, however, that the increased number of groups was 
accompanied by a higher DBI value (0.91 for 3 groups vs. 0.75 for 2 groups), suggesting 
that 2 groups better describe this particular population of action potentials. 
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Figure 2.6 Spatial maps of different AP parameters or groups for five different cell 
clusters. Top four rows: Spatial distributions of APD30, APD80, fractional repolarization, 
and triangulation in the clusters. Iso-parameter contours have 10 ms spacing for APD30, 
APD80 and triangulation and 0.05 spacing for fractional repolarization. Maps in the same 
row share same color bar. Bottom two rows: Grouping resulting from the automated 
algorithm and assumption of 2 (second to last row) or 3 (last row) groups. Colors signify 
different groups assigned by the algorithm. Columns: clusters 4, 7, 9, 24 and 27. 
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For visualization and discussion purposes, all APs were plotted as scatter plots of 
joint distributions of pairs of AP parameters, along with their group labels by waveform 
analysis in colors (Fig. 2.7). Although paced at the same rate, the entire set of APs 
encompassed a large area in all 2D spaces of AP parameter pairs, indicating a high degree 
of variability. When APs were divided into two groups, they occupied relatively distinct 
regions in all 2D spaces. Linear boundaries were determined by SVMs within each 2D 
space, and shown as dashed lines. The degree of overlap of the two groups was defined as 
the total percentage of APs of each group located outside the boundary of their respective 
groups, and ranged from 0.9% to 8.1% across all of the 2D spaces, indicating the influence 
of features of AP shape not captured by just a pair of AP parameters. In general, the overlap 
in the 2D spaces with AP duration parameters (Fig. 2.7A) was smaller than that in 2D 
spaces with triangulation and fractional repolarization parameters (Fig. 2.7F), suggesting 




Figure 2.7 Pairwise scatter plots of individual AP parameters for all recorded APs, 
color-coded by grouping results defined by waveform analysis. Dashed lines indicate 
linear decision boundaries separating the two groups in the parameter space, derived by 
support vector machines. APs of each group falling on the opposite side of the boundary 
(the overlaps, highlighted in green) were quantified as percentage of the total APs and are 
given above each panel. 
Rate dependency 
Depending on the cluster, electrical pacing could stimulate APs up to 330 bpm 
while maintaining 1:1 capture, allowing the study of the rate-dependence of paced APs 
(Fig. 2.2B) and whether rate-dependency could be an additional means by which different 
sub-populations (phenotypes) of cells could be discriminated. In a cluster having two 
regions with different AP durations (cluster 26), electrical pacing was applied from 90 to 
180 bpm in 30 bpm increments. While all recording sites (n=585) in this cluster had rate-
dependent shortening of APD80, the rate-dependencies of fractional repolarization varied 
greatly, being positive (increased fractional repolarization with increased rate) in some 
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regions (n=180) and negative in others (n=405). Two representative recordings from this 
cluster and their corresponding APD80 and fractional repolarization rate-dependencies are 
shown in Fig. 2.8. The differences in rate-dependencies suggest that the use of multiple 
pacing rates may further assist in identifying phenotypic differences.  
 
Figure 2.8 Rate-dependence of action potentials in a cell cluster (cluster 26). (A) 
Action potentials recorded from two different locations in the cluster having long (left, red 
traces) and short (right, blue traces) APs, at 90, 120, 150 and 180 bpm pacing. (B) Rate-
dependence of APD80 at the two recording sites. (C) Rate-dependence of fractional 
repolarization at the two recording sites. 
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2.3.2 Action potential variability in hiPSC-CM monolayers 
General electrophysiological properties of hiPSC-CM monolayers 
A PDMS stencil was used to restrict the growth area of hiPSC-CM monolayers 
(Fig. 2.9A) and effectively control the size and shape of the monolayers. Approximately 
two days after monolayer plating, spontaneous beating was observed across the 
monolayers, with beating often originating from different locations across the monolayer. 
These asynchronous spontaneous activities gradually become synchronized over time in 
culture, indicating formation of a functional syncytium. 
When electrical point pacing was applied at the edge of the monolayer, smoothly 
propagating action potentials could be initiated across the monolayer. A representative 
activation map is shown in Fig. 2.9B, where the pacing was applied at the upper left corner 
of the monolayer. The average conduction velocity measured at 1000 ms cycle length for 
WT11 hiPSC-CM monolayers was 12.1±3.4cm/s (n=3 monolayers), which is substantially 
slower than typical conduction velocities measured in adult myocardium (41.4±3.4cm/s, 
transmural) (Glukhov et al., 2010). The contour lines show isochrones of activation times. 
Typically, a smooth propagation pattern was observed, with no significant slowing or other 
abnormality that may indicate conduction heterogeneity. These observations reinforce the 
notion that hiPSC-CM monolayers are an electrically functional syncytial model. 
 40 
 
Figure 2.9 General electrophysiological properties of hiPSC-CM monolayers. (A) 
Schematic diagram of PDMS stencil used to restrict the growth area to a 10 mm diameter 
circle in a 35 mm dish. (B) Representative activation map of an hiPSC-CM monolayer 
when electrically paced at 1000 ms cycle length. Blue indicates regions activated at an 
earlier time, red indicates regions activated later. Isochrones show area activated at the 
same time, and are drawn at 10 ms intervals as indicated. Scale bar is 1 mm. (C) Action 
potentials recorded from the hiPSC-CM monolayer shown in B. Solid line is the action 
potential averaged over the entire monolayer. Shaded area is an overlay of individual action 
potentials recorded from each recording site of the monolayer. (D) APD80 (blue) and APD30 
(red) histograms of this monolayer, showing 5890 recording sites. Bar on top of blue 
histogram indicates IQR-APD80. 
Action potentials recorded from different recording sites are demonstrated in Fig. 
2.9C for this example monolayer. The solid line indicates the average of all action 
potentials recorded across the entire monolayer, representing the aggregate 
electrophysiology of the monolayer. The lighter traces show superimposed action 
potentials from 5890 individual recording sites in this monolayer, representing local 
electrophysiology at different sites within the monolayer. As shown in this example, action 
potentials recorded from individual sites deviate slightly from the average, but in general 
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follow the same morphology. This observation is also evident when APD80 and APD30 are 
used as measures of the action potentials, which is shown in Fig. 2.9D. Only a single peak 
was observed for both APD80 and APD30 histograms, further indicating relatively uniform 
action potential properties and a single electrophysiological phenotype. The variation of 
action potential durations was measured by the interquartile range of APD80 (IQR-APD80). 
In this example, the IQR-APD80 was 16 ms, which was very narrow compared to the 
average APD80 of 370 ms. Similar observations of a single peak histogram for APD80 were 
observed in all other monolayers analyzed (n=9). These observations suggest only one 
phenotype is present in hiPSC-CM monolayer cultures. 
Effect of IKr blockade on action potential variability in hiPSC-CM monolayers 
The effect of ion channel blockade on action potential variability was investigated 
by pharmacologically blocking IKr, an important repolarizing current in the 
cardiomyocytes. For this purpose, E-4031, a specific IKr blocker was applied to hiPSC-CM 
monolayers. E-4031 induced a concentration-dependent prolongation in the average action 
potential of the monolayer (Fig. 2.10A). The action potential also had slower repolarization 
and become more triangular in morphology. The monolayers remained captured to 1000 
ms cycle length electrical pacing, and no ectopic activity was observed with E-4031.  For 
individual recording sites across the monolayer, action potentials across again deviated 
only slightly from the average action potential (Fig. 2.10B, lighter traces are overlays of 
individual APs, solid lines are average APs). The application of E-4031 did not create 
separation in action potential morphologies, consistent with a single phenotype even with 
IKr blockade. The APD80 histograms (Fig. 2.10C) showed a rightward shift with increasing 
concentration of E-4031, and a slight increase in spread in this example, but remained 
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having a single peak. The box plots of APD80 (Fig. 2.10D) also show this pattern, with 
concentration-dependent prolongation in APD80, but only a very slight increase in APD80 
variability When measured over multiple monolayers (n=3), IQR-APD80 was not affected 
by E-4031 in a statistically significant way (Fig. 2.10E). Further, conduction velocity 
remained the same with or without E-4031 (Fig. 2.10F).  
Spatially, clustering of APs with similar durations was also observed in hiPSC-CM 
monolayers, similar to observations with hEBs (Fig. 2.6), except that a single peak in 
APD80 histogram was always observed, unlike the multiple peaks often observed in hEBs 
(Fig 2.3). E-4031 also did not change the clustered distribution of action potentials (Fig. 
2.10G a-d). Activation maps at baseline and all E-4031 concentrations tested showed 
homogeneous AP propagation, with no conduction slowing or block (Fig. 2.10G e-h). 
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Figure 2.10 Effect of IKr blockade on action potential variability in hiPSC-CM 
monolayers. (A) Average action potential across a single hiPSC-CM monolayer, at 
baseline and with different concentrations of E-4031. (B) Average APs (solid line) and 
individual APs within the monolayer at baseline and with 100 nM E-4031. (C) APD80 
histograms at baseline and with different concentrations of E-4031, showing 6592 
recording sites. (D) Box blot of APD80 of action potentials within the same hiPSC-CM 
monolayer. Box indicates interquartile range, whiskers indicate 5th and 95th percentiles. (E) 
Relative change in IQR-APD80 in response to E-4031. (F) Relative change in conduction 
velocity in response to E-4031. (G) a-d. APD80 variability maps of an hiPSC-CM 
monolayer at baseline or with E-4031. Blue indicates areas with APD80 shorter than the 
median APD80 across the monolayer, red indicates areas with APD80 longer than the 
median. e-h. activation maps of the same monolayer at baseline or with E-4031. (E-F) n=3 
monolayers, all ns compared to baseline. 
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Effect of acute electrical uncoupling on action potential variability in hiPSC-CM 
monolayers 
In a syncytial monolayer, cardiomyocytes are electrically coupled through gap 
junctions among cells. Therefore, it is possible that electrical coupling could reduce the 
intrinsic AP variability by smoothing differences among neighboring APs. To test whether 
electrical uncoupling can reduce action potential variability, carbenoxolone (CBX), a gap 
junction blocker, was applied acutely to hiPSC-CM monolayers. IKr blockade was then 
repeated in the presence of CBX to investigate any additional effect on action potential 
variability. 
Application of 50 μM CBX slightly prolonged the average action potential of the 
hiPSC-CM monolayer (Fig. 2.11A). The APD80 histogram showed a slight rightward shift 
in the population action potentials, but remained having a single peak (Fig. 2.11B). The 
IQR-APD80 did not change significantly either (Fig. 2.11D). Conduction velocity was 
significantly slowed with CBX, as expected with a decrease in electrical coupling (Fig. 
2.11C), which is also evident in compression of the isochrone lines in the activation maps 
(Fig. 2.11E f-g). The spatial distribution of APD80 was not affected by carbenoxolone (Fig. 
2.11E a-b). Further blockade of IKr by E-4031 led to a concentration-dependent 
prolongation of action potential that was similar to the non-CBX results. The APD80 
histogram slightly widened but remained having a single peak and the IQR-APD80 did not 
deviate significantly from baseline (Fig. 2.11D), supporting the notion of a single 
predominant phenotype in the monolayer. However, in contrast to non-CBX conditions, 
IKr blockade with CBX led to further concentration-dependent slowing in conduction (Fig. 
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2.11C). On the other hand, despite conduction velocity slowing, there was no change in the 
pattern of action potential propagation (Fig. 2.11E f-j). 
 
Figure 2.11 Effect of acute electrical uncoupling on action potential variability. (A) 
Average action potentials of hiPSC-CM monolayer with CBX and E-4031. (B) APD80 
histogram of action potentials from a total of 6311 recording sites within the monolayer. 
(C) Relative change in conduction velocity in response to CBX and E-4031. (D) Relative 
change in IQR-APD80 in response to CBX and E-4031. (E) a-e. APD80 maps at different 
CBX concentrations; blue indicates regions with APD80 shorter than the median, red 
indicates regions with APD80 longer than the median. f-j. activation maps of the monolayer 
at different CBX concentrations. (C-D) n=5 monolayers, * indicate significant (p<0.05) 
compared to baseline (100%). 
Comparison between in-house derived and commercially available hiPSC-CMs 
Action potential variability was compared between monolayer cultures of in-house 
differentiated WT11 hiPSC-CMs and commercially available Axiogenesis Cor.4U 
cardiomyocytes. The Cor.4U cells are purified human iPSC-derived cardiomyocytes with 
approximate composition of 60%-20%-20% ventricular-like, atrial-like and nodal-like 
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phenotypes identified by patch clamp of single cells (Kettenhofen et al., 2014). However, 
when cultured as monolayers the cells reveal just a single predominant electrophysiological 
phenotype. The implication of a single phenotype within hiPSC-CM monolayers on their 
drug responses is further discussed in Chapter 4.  
 
Figure 2.12 Comparison of action potential variability between monolayers consisting 
of in-house or commercial hiPSC-CMs. (A) Action potentials recorded from multiple in-
house monolayers. (B) APD80 histograms of corresponding monolayers in A. (C) Action 
potentials recorded from multiple commercial monolayers. (D) APD80 histograms of 
corresponding monolayers in C. (B,D) number of recording sites within each monolayer 
are as indicated. 
Action potentials recorded from both in-house derived iPSC-CM monolayers (Fig. 
2.12A) and Cor.4U monolayers (Fig. 2.12C) were always uniform within individual 
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monolayers, with only small variations. This is also evident in the APD80 histograms (Fig. 
2.12B for in-house monolayers and Fig. 2.12D for Cor.4U monolayers). However, it is also 
worth noting that, overall the action potentials were more uniform across multiple Cor.4U 
monolayers than across multiple in-house derived monolayers, presumably due to the more 
stringent quality control in the production of the Cor.4U cells. The in-house monolayers 
had an IQR-APD80 of 39±19 ms (mean±SD) and an inter-monolayer SD of average APD80 
of 26 ms (n=9), while the Cor.4U monolayers had an IQR-APD80 of 13±5 ms and an inter-
monolayer SD of average APD80 of 14ms (n=9). For comparison, the hEBs had an IQR-
APD80 of 23±12 ms (mean±SD) and an inter-hEB SD of average APD80 of 37 ms. To 
account for the differences in pacing rates between hEB and monolayer experiments (90 
bpm for hEBs and 60 bpm for monolayers), IQR-APD80 was normalized to the average 
APD80, and the ratio of IQR-APD80 to APD80 was 0.17±0.10, 0.14±0.07 and 0.03±0.01 
for hEBs, in-house monolayers and Cor.4U monolayers, respectively. 
2.4 Discussion 
Manifestation of action potential variability in cluster and monolayer models 
Electrophysiological variability observed in hPSC-derived cardiomyocytes is an 
undesired property for many in vitro applications. For example, in regenerative medicine, 
heterogeneous action potentials can be problematic as they can create a proarrhythmic 
substrate. The nodal-like cells may also become ectopic pacing sites if integrated in host 
tissue. Another example is in in vitro testing of drug responses using hPSC-derived 
cardiomyocytes. Variability in electrophysiology creates a heterogeneous baseline which 
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makes interpreting drug responses more difficult and less reliable. The action potentials of 
hPSC-CMs are generally recognized as heterogeneous and not fully like adult phenotypes 
(Blazeski et al., 2012b; 2012a), but to date the largest population in which this variability 
has been studied was 134 cells (López-Redondo et al., 2016). The results in this chapter 
characterized AP variability in two different in vitro hPSC-CM models: small clusters of 
hESC-derived cardiomyocytes, which had 722±252 (n = 32) recording sites with 16 μm 
resolution and large monolayers of hiPSC-derived cardiomyocytes, which had 6609±464 
(n = 18) recording sites with 100 μm resolution. 
Small clusters of hESC-CMs provide a platform to investigate how electrical 
variability manifests both within the same cluster and among clusters from the same 
differentiation batch. This can help in the understanding of the smallest spatial scale at 
which action potential variability becomes significant. Prior studies using microelectrode 
impalements of hEBs showed that APs differed substantially among different hEBs but 
were mostly similar within individual clusters (He et al., 2003; Jonsson et al., 2010), 
although the sample size obtained per cluster was small and limited by the experimental 
methods. However, the large population analyses in this chapter show that APs vary over 
a wide range across hEBs and over a smaller, but still substantial range within hEBs. 
Further, although numerous research groups have reported percentages of nodal-like, 
atrial-like and ventricular-like cells at a stage of differentiation similar to the clusters 
studied in this chapter (20-24 days) (Fu et al., 2011; Lee et al., 2011; Lieu et al., 2013; 
Moore et al., 2008), the results here demonstrate that different phenotypes are difficult to 
distinguish for at least two reasons: 1) individual parameters are insufficient to divide 
populations of APs into different groups, since APs with similar parameter values (such as 
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APD80) could have very different morphology indicative of different phenotypes, and 2) 
the wide range and continuous variability of APs make it extremely difficult to subjectively 
determine cut-offs between groups. However, by using an automated grouping algorithm 
that utilized the entire AP waveform shape, the AP dataset could be objectively separated 
into 2 or 3 maximally separated groups. 
Cardiac cell clusters derived from hEBs are self-assembled, three-dimensional 
aggregates. This three-dimensional organization provides a natually formed 
microenvironment for hPSC-derived cardiomyocytes, allowing them to grow and remodel 
their surrounding extracellular matrix, to undergo paracrine and autocrine signaling, and to 
contract against a compliant mechanical load. However, the microenvironments 
experienced by cells in each cluster are independent of one another and not necessarily the 
same. The hEB-based differentiation protocol (Burridge et al., 2011; Burridge and 
Zambidis, 2013) used here has high efficiency, so that a large number of beating hEBs can 
be generated within a single differentiation batch sufficient for studies of variability 
introduced under culture conditions. Some sources of variability were managed. Optical 
mapping was performed on beating cell clusters within a narrow time window, 21-24 days 
after initiation of differentiation. Fixed-rate pacing was used so that APs could be 
compared at the same beat rate. However, there remained several uncontrolled 
experimental variables. Although similar numbers of hESCs were seeded to form hEBs, 
the ensuing hEBs still had different sizes, shapes and beat rates, which could influence the 
differentiation process. In addition, the beating cardiac cell clusters that were mechanically 
dissected from the hEBs may represent only a subset of all of the cardiomyocytes that were 
present. Also, the uncontrolled amount of nonmyocytes in the cell aggregates can influence 
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the maturation of the embedded hESC-CMs (Kim et al., 2010a). The action potential 
variability observed within and across hEBs is a combined result of these environmental 
factors, and reflects the adaptability of hPSC-CMs and their electrophysiology to the local 
microenvironment. 
High-resolution measurements of early differentiated clusters suggest that a 
relatively broad distribution of APs is present within the clusters (Fig. 2.3), although not 
as broad as across the entire set of 32 clusters that was studied. In many, but not all clusters, 
a histogram of APD80 that was either narrow or else wide with multiple peaks was 
observed, suggestive of one or multiple predominant phenotypes. APD30, triangulation and 
fractional repolarization are other ways to quantify the plateau and repolarization phases 
of the AP, which in turn are manifestations of the underlying ion currents which have 
differing temporal and voltage-dependent kinetics (Shah et al., 2005). APD30 is a rough 
measure of plateau duration, while APD80 is a measure of the combined plateau and 
repolarization durations. Triangulation (Hondeghem et al., 2001) is roughly the duration of 
phase 3 repolarization, and is considered to be proarrhythmic when prolonged. Fractional 
repolarization is the fraction of the total APD involved with phase 3 repolarization. This 
parameter is also akin to the comparison between plateau (duration between APD30 and 
APD40) and repolarization (duration between APD70 and APD80) phases defined by others 
to distinguish between ventricular-like cells and atrial-like cells (Ma et al., 2011). In this 
study, the spatial patterns of groupings based on APD80, APD30, triangulation and fractional 
repolarization were usually but not always concordant with one another (Fig. 2.6), raising 
the question of which parameter(s) is most important for phenotype identification. 
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Given that variability exists within and among small sized, independent groups of 
hPSC-CMs, it is also important to know if they retain their variable action potential 
properties when allowed to interact and form a larger syncytium. In fact, a recent study has 
demonstrated that geometric shape and size can affect action potentials in hiPSC-CMs, 
where larger aggregates of cells tend to have more mature electrical and calcium dynamics 
(Werley et al., 2017), although the largest island tested was 1 mm × 1 mm. The larger 
monolayers used in this chapter provide a model for further investigating this question. 
Individual hiPSC-CMs are heterogeneous and comprised of all three phenotypes, as is the 
case for Axiogenesis Cor.4U cardiomyocytes, which have been characterized by the 
manufacturer to have a mixed population of nodal-, atrial- and ventricular-like cells at 
expected fractions of 20%, 20% and 60% respectively. However, the action potentials 
within individual monolayers in fact had similar shapes, rather than distinctly different 
shapes, suggesting that the cell monolayers, despite being much larger in dimension than 
hEBs, promote the convergence of the hiPSC-CMs to a single predominant 
electrophysiological phenotype. This phenotype convergence is evident in two ways. First, 
monolayers had a lower inter-sample variability than hEBs, which is indicated by the lower 
SD of average APD80 (26 ms and 14 ms for in-house and Cor.4U monolayers, respectively, 
compared to 37 ms for hEBs), and second, variability within each sample, as measured by 
the ratio of IQR-APD80 to APD80 to account for pacing rate differences, was also lower in 
in-house and Cor.4U monolayers than in hEBs (0.14±0.07 and 0.03±0.01 compared to 
0.17±0.10). It is worth noting that the size of the hEBs is much smaller than the monolayers 
(hundreds of microns vs. 1 cm diameter), and despite the higher spatial resolution used for 
hEBs (16 μm/pixel vs. 100 μm/pixel for monolayers), the number of recording sites within 
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hEBs was still much smaller than within monolayers (722±252 vs. 6609±464, 
respectively). The hEBs were also paced at a higher rate of 90 bpm compared to 60 bpm 
for the monolayers. These factors could contribute to an underestimation of variability 
observed in hEBs. 
Unlike spontaneously-formed hEBs, monolayers provide a more consistent 
microenvironment during culture. Cardiomyocytes in monolayers have more uniform 
access to nutrients and growth factors present in the culture medium, experience similar 
biomechanical stimuli from the culture substrate to which they are attached, and once 
electrically coupled, have the same spontaneous activity and therefore bioelectrical signals. 
Individually, these environmental factors have been shown to affect the electrophysiology 
in hPSC-CMs (Zhu et al., 2014). Therefore, the uniformity observed in monolayers is 
possibly a combined result of uniformity of these environmental factors. 
The action potential is an aggregate measurement of hPSC-CM electrophysiology, 
and is generated by the coordinated activity of multiple ion currents. Different ion current 
compositions can, however, result in a similar action potential waveform. If this is the case, 
selective blockade of individual ion currents may reveal an underlying ion current 
heterogeneity in a population of cells by disturbing their balance in a differential manner, 
changing the action potential in different, revealing ways. However, the monolayer 
response to IKr blockade with E-4031 suggests the contrary. IKr is one of the most important 
currents that activates during repolarization of the action potential, and strongly affects 
action potential morphology and duration. However, blockade of this important current did 
not lead to separation of the APD80 histogram into multiple peaks, separation of regions of 
the monolayer into different phenotypes, or even a significant increase in AP variability as 
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quantified by IQR-APD80. These observations suggest that the similarity in action 
potentials within hiPSC-CM monolayers reflects a uniformity in ion current composition 
(at least, for IKr) across the monolayer, which is further indicative of a single 
electrophysiological phenotype. 
Gap junctions connecting cardiomyocytes can also make action potentials appear 
to be similar through cell-cell electrotonic coupling. However, decrease of electrical 
coupling by carbenoxolone did not lead to phenotype separation nor increase in action 
potential variability, suggesting an electrical smoothing effect was not responsible for the 
similarity in action potentials. It is worth pointing out that although carbenoxolone only 
reduced conduction velocity by a small percentage, this is reflective of a much larger 
reduction in intercellular coupling (Kléber and Rudy, 2004). With reduced electrical 
coupling, E-4031 produced a dramatic reduction in conduction velocity while it did not 
with normal electrical coupling. This result can be explained as follows. The prolongation 
of action potential by E-4031 reduced the diastolic interval following the action potential, 
thereby impairing excitability and slowing down conduction of the next action potential. 
With normal electrical coupling, this reduction in excitability was insufficient to impair 
conduction because of conduction reserve in the tissue (van Rijen et al., 2006), but with 
reduction of electrical coupling by CBX, conduction reserve is diminished, thereby 
augmenting the slowing effects of E-4031. 
In hEBs, clustering of cells having similar action potential phenotypes was 
observed. Similarly, this was also the case for monolayers. E-4031 or CBX did not 
significantly change the local clustering of electrophysiologically similar cells, except at a 
high concentration of E-4031 where there was a slight dissipation of clustering towards an 
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intermixed distribution. This can be explained if the electrophysiological variability 
underlying clustering is due in large part to IKr, which becomes nearly completely blocked 
at the high concentration of E-4031. Similar to small clusters, hPSC-CM monolayers also 
contain cardiomyocytes that are electrically and mechanically coupled, which are potential 
pathways to modulate the electrophysiology of individual cells that could work over long 
range distances of multiple cell dimensions. Therefore, monolayer experiments can provide 
insight on how does this homogenizing effect extend to much larger physical dimensions 
when cells are cultured as larger scale monolayers. 
The main difference between in-house derived hiPSC-CMs and commercially 
available cells lies in their quality control. Industrial production of hiPSC-CMs requires 
higher scalability and reproducibility than cardiac differentiations in a research 
environment. Good Manufacturing Practice (GMP) compatibility is also taken into 
consideration for commercial hiPSC-CMs, as it is a requirement for pharmaceutical and 
clinical applications. The differences in practices can affect the quality of hiPSC-CMs in 
several ways. For example, despite generally high differentiation efficiency with the 
monolayer-based protocol, there is inevitably some variable amount of non-myocytes left 
in the in-house hiPSC-CM differentiations that contributes to the variability in 
experimental observations, which is not strictly controlled. This is not the case of Cor.4U 
hiPSC-CMs, where purification methods are used to ensure near 100% cardiomyocytes. In 
addition, the consistency in culture conditions is also subject to more variability for in-
house production of hiPSC-CMs than for commercial production, such as the batch-to-
batch variability in research-only grade reagents, the more frequent access to the cells in 
the incubator which could disturb the culture environment, and the variability in culture 
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handling among researchers. The combination of the above-mentioned factors, along with 
others, could explain the observation that commercial cells are much more uniform in 
electrophysiology, both within the monolayer, and across monolayers compared to in-
house hiPSC-CM monolayers. 
Phenotype identification in hPSC-CMs 
The gold standard for identifying phenotypes of cardiomyocytes derived from 
hPSCs is still under debate (Kane and Terracciano, 2017). The most accepted method is 
comparison of the immature phenotype found in hPSC-CMs with that of mature human 
cardiomyocytes. This include features such as molecular cellular markers, cellular 
morphological characteristics and action potential properties. However, molecular cellular 
markers are currently limited primarily to MLC2v or IRX-4 for the ventricular subtype 
(Karakikes et al., 2014; Otsuji et al., 2010; Zhang et al., 2011) and cannot be used on live 
cells. In practice, classification by AP morphology is still the most widely adopted method 
by which cardiomyocyte phenotypes have been assessed by microelectrode or optical 
recordings (Ardehali et al., 2013; Du et al., 2015; Fu et al., 2011; Lee et al., 2011; Leyton-
Mange et al., 2014; Tohyama et al., 2013; Wang et al., 2011), although there are also 
questions on the utility of this approach (Bett et al., 2016; Du et al., 2015; Giles and Noble, 
2016; Kane et al., 2016). Major subtypes of hPSC-CMs (nodal-like, atrial-like, ventricular-
like) have most often been identified subjectively by the similarity of their AP shapes to 
those of the adult phenotypes. Only a few studies specified quantitative criteria for 
classification in terms of AP parameters, including APD90 (Peng et al., 2010), combination 
of APD90 and beat rate (Jonsson et al., 2010), ratio of APDs (Chan et al., 2013; Ma et al., 
2011), and a combination of AP amplitude, upstroke velocity, APD50 and APD90 (Fu et al., 
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2011; Lieu et al., 2013). The hEB classification results of this chapter show that grouping 
by histogram analysis of single parameters does not assure consistent AP morphology; 
action potentials having the same APD80 or APD30 can have differing AP shapes reflecting 
different phenotypes (Fig. 2.5C and 2.5D). Increased numbers of parameters result in 
improved grouping, with the ultimate representation being the entire waveshape. 
Analysis of the entire data set of APs (recorded across 32 hEBs) by an automated 
machine learning algorithm (Gorospe et al., 2014) divided the APs into different groups 
based on their waveshape and similarity to one another. This method also produced the 
most distinctive differences in AP waveforms between groups (Fig. 2.4F). Within 
individual hEBs the groups occupied separate spatial regions rather than being intermixed, 
even though the automated algorithm did not incorporate spatial information. This finding 
suggests that physical location or cell-cell interactions can influence phenotypic 
specification during hESC-CM differentiation and maturation, which is manifested in the 
local distribution patterns of individual parameters (Fig. 2.6). The use of the entire set of 
APs across all clusters also enabled cells that belong to same group to be identified in 
multiple clusters (Fig. 2.6), which would not be possible by separate analyses of individual 
clusters. It should be noted that although APs were divided into 3 groups, those groups do 
not necessarily correspond to nodal-, atrial- and ventricular-like cells, but perhaps, to 
precursor or intermediate stage cells. Further studies are warranted to develop more 
advanced methods for AP shape analysis and ultimately, phenotypic classification.  
A further improvement for the discrimination of different phenotypes, which has 
not been employed so far by other laboratories, is the use of different pacing rates, which 
takes advantage of the different rate-dependent kinetic properties of the ion currents 
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underlying the AP. As shown in one example, with increasing rate, APD80 decreases across 
the cluster, whereas fractional repolarization may change in opposite directions in different 
regions of the cluster (Fig. 2.8). 
Strength and limitations of optical mapping 
Sharp microelectrodes and multiple impalements have been used to study the 
variability in electrophysiology of hEBs (He et al., 2003; Peng et al., 2010), but in practice 
are limited to around 10 measurements or less per hEB. In contrast, optical mapping is a 
more flexible approach for measuring action potentials in hPSC-CMs. When used in a plate 
reader-like system (CellOPTIQ, Clyde Biosciences), average action potentials can be 
recorded from small groups of cells with relatively high throughput (Hortigon-Vinagre et 
al., 2016). When used in a high-resolution setup such as the system used in this thesis, 
hundreds to thousands of recordings can be obtained from hEBs or monolayers. With the 
right combination of optics, a field of view larger than 1 cm × 1 cm used here can be 
achieved for measurements in an even broader tissue context. With the development of 
genetically encoded voltage sensors, it has also become possible to measure action 
potentials from a specific promoter-driven subpopulation of cardiomyocytes (Chen et al., 
2017). However, there are also limitations to the optical mapping approach. First, there are 
limits on true spatial resolution, owing to diffuse light scattering of the fluorescent signal 
and volume integration of signals along the recording path (Bishop et al., 2007; Ding et al., 
2001). Electrical coupling among neighboring cells can also electrically average APs 
within close proximity, though this would also affect other experimental methods such as 
MEAs. The boxcar (for hEBs) or Gaussian (for monolayers) filter applied in the data 
analysis, which was necessary to improve signal quality, also limits the spatial resolution 
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in this method. Another limitation of optical measurements is that they measure only 
relative changes in transmembrane voltage and not absolute values (unless advanced 
methods such as dual wavelength measurements and microelectrode calibration are used) 
(Entcheva and Bien, 2006; Fast, 2005). Nevertheless, they have fast responses that can 
faithfully track the transmembrane voltage and preserve AP shape (Girouard et al., 1996; 
Tritthart, 2005). 
Conclusions 
In conclusion, intrinsic variability in electrophysiology was found in small clusters 
of hPSC-CMs, resembling different phenotypes. The phenotypes can be identified by a 
waveform-based algorithm. This electrophysiological variability was found to be greatly 
reduced in large monolayer cultures for both in-house and commercially available hPSC-
CMs, suggesting that large monolayer culture promotes similarity in the 





Chapter 3  
Modeling type 2 long QT syndrome with human 
iPSC-CMs 
3.1 Introduction 
Genetic mutations can cause various types of heart disorders, many of which can 
lead to life threatening arrhythmias. Among these conditions, long QT syndrome (LQTS) 
is characterized in vivo by a prolonged QT interval in the patient’s ECG, and is 
accompanied by increased risk of a specific type of polymorphic ventricular tachycardia 
known as Torsades de Pointes (TdP). In inherited LQTS patients, mutations in different 
cardiac ion channels can cause imbalance of ion currents during repolarization of cardiac 
action potentials, leading to prolonged QT intervals. A notable example is type 2 LQTS 
that represents approximately 45% of known LQTS defects (Splawski et al., 2000). In this 
LQTS family, a reduction in rapid delayed rectifier K+ current (IKr) caused by mutations 
in its alpha subunit, known as Kv11.1, encoded by the human Ether-a-go-go Related Gene 
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(hERG) is responsible for the prolonged QT interval. These hERG mutations have been 
extensively studied using heterologous expression systems, typically in HEK 293 cells, 
revealing different mechanisms of mutation-induced IKr reduction, including disruption of 
channel synthesis, gating, permeation and most commonly, impaired protein trafficking 
(Anderson et al., 2006; 2014). Temperature and pharmacological correction strategies have 
also been evaluated using heterologous systems, and were shown to have different efficacy 
depending on the location and nature of the mutation (Guo et al., 2012; Smith et al., 2016). 
More recently, the development of cardiac differentiation using human induced 
pluripotent stem cells has provided unique opportunities to study inherited heart disorders 
in a human cardiomyocyte context. These cardiomyocytes, differentiated from patient-
specific hiPSCs, preserve the genotype of their donor, making them a promising in vitro 
substitute to native tissue for physiological studies. LQTS was among the first congenital 
heart diseases being modeled (Moretti et al., 2010), and is one of the most extensively 
studied diseases using hiPSC-CMs, in part because most LQTS subtypes are caused by a 
single gene mutation, making genotype identification relatively straightforward (Tester and 
Ackerman, 2014). At the cellular level, cardiomyocytes recapitulate the LQT2 phenotype 
in several hiPSC-CM lines carrying hERG missense mutations (Bellin et al., 2013; Matsa 
et al., 2011; Mehta et al., 2014b; Spencer et al., 2014), and respond to rescuing strategies 
found effective with heterologous systems, validating their potential use in studies of 
inherited LQTS. However, few studies are available on the tissue properties of in vitro 
hiPSC-CM syncytial models. 
First identified in an Asian family with LQT2, the hERG-A422T mutation has been 
shown to cause dominant-negative suppression of WT hERG when expressed in HEK 293 
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cells (Guo et al., 2012; Sharma et al., 2004). Further investigation suggested that this 
missense mutation, like most other hERG missense mutations, caused immature mutant 
hERG protein to be retained in the endoplasmic reticulum in HEK 293 cells, resulting a 
trafficking defect, which can be partially rescued by incubation with pharmacologic 
chaperone E-4031 or low temperature (Guo et al., 2012). Recently, a human iPS line 
derived from a patient with A422T mutation (LQT2-A422T) has been established, and 
cardiomyocytes derived from these cells have been reported to have prolonged AP duration 
and Ca2+ transients that are consistent with the LQT2 phenotype (Spencer et al., 2014). In 
this study, the in vitro LQT2 model is further explored in a syncytial context, and 
electrophysiological assays are performed to characterize the LQT2 phenotype associated 
with this heterozygous A422T mutation. The effect of IKr activation is also evaluated as a 
potential rescuing strategy for this LQT2 model. 
3.2 Methods 
3.2.1 Cell culture and cardiomyocyte differentiation 
For comparison with LQT2-A422T hiPSCs, human iPS cells from an unrelated 
patient with no known cardiac disease was used as control, which is referred to as wild type 
(WT, which is the same as the WT11 line used in Chapter 2). WT and LQT2-A422T 
human iPSCs were maintained feeder-free as monolayers in Essential 8 medium 
(ThermoFisher). Cardiac differentiation was performed by timed modulation of the Wnt 
pathway as previously described (Boheler et al., 2014; Wang et al., 2015). Beating 
cardiomyocytes were dissociated with 0.05% Trypsin (ThermoFisher) and re-plated for 
different assays. For optical mapping, cells were plated at 3x105 cells/cm2 on Geltrex 
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(Gibco)-coated 35 mm tissue culture dishes, where the growth area was restricted by a 
PDMS stencil to a 10 mm diameter area to match the field of view of the camera system. 
Similar to Chapter 2, the monolayers were kept in culture for 35-55 days total after 
initiation of differentiation before proceeding further with experiments. A small percentage 
of monolayers that detached from the culture dish during this time were excluded from 
experiments. 
3.2.2 Molecular biology 
Flow cytometry 
WT and LQT2-A422T cardiomyocytes were dissociated by 0.05% Trypsin into 
single cells for flow cytometry. Cells were fixed with BD Cytofix and permeablized with 
BD Phosflow (both from BD Biosciences) per manufacturer’s instructions. Primary 
antibody against cardiac troponin T (ThermoScientific MS-295-P, 4 μg/200 μL) was used 
to identify cardiomyocytes. Mouse IgG1 control (Life Technologies MG100, 4 μg/200 μL) 
was used as isotype control. Cells were stained with Alexa Fluor 488 goat anti-mouse IgG1 
antibody (Life Technologies, A21121, 0.6 μg/200 μL) for visualization in the flow 
cytometer. A BD FACSCalibur cell analyzer was used to perform flow cytometry, and a 
total of 50,000 events was recorded for each condition. 
RT-PCR 
Total mRNA of WT and LQT2-A422T cardiomyocytes was extracted by the 
TRIzol-based protocol. The quantity and quality of extracted mRNA was measured by a 
NanoDrop Spectrophotometer. A total of 2 μg mRNA was reverse transcribed with a 
commercial kit (Applied Biosystems). The product cDNA was used for downstream PCR 
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analysis. Primer pairs used to amplify WT- or mutant-specific KCNH2 mRNA are 
summarized in Table 3.1. PCR reaction was performed with PCR master mix (Bimake) in 
a Technic ATC 401 thermal cycler. The PCR product was analyzed by electrophoresis in 
1% agarose gel and visualized by SYBR Safe DNA Gel Stain (ThermoFisher). 










For western blot, total protein was harvested using RiPA buffer (ThermoFisher). 
For Proteinase K treated samples, cells were first incubated with 200 μg/mL proteinase K 
(Sigma-Aldrich) in buffer containing 10 mM HEPES, 150 mM NaCl and 2 mM CaCl2 for 
30 min, followed by inactivation of proteinase K by ice cold PBS containing 6 mM PMSF 
(Sigma-Aldrich) and 2 mM EDTA (ThermoFisher). All samples were then resolved using 
NuPAGE 4-12% SDS-polyacrylamide gel (ThermoFisher) by electrophoresis. Separated 
proteins were transferred on a PVDF membrane using the iBlot2 Transfer Stacks with the 
iBlot 2 dry blotting system (both from ThermoFisher). The membrane was then blocked in 
10% milk in Tris-buffered saline and stained with mouse anti-hERG monoclonal antibody 
(Santa-Cruz, sc-377388, 1:100) and mouse anti-GAPDH monoclonal antibody (EMD 
Millipore, MAB374, 1:1000) overnight at 4°C, and then stained with goat anti-mouse IgG 
IRDye secondary antibody (LI-COR, 1:10000). The membrane was visualized using the 
Odyssey imaging system (LI-COR). 
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Immunocytochemistry 
For immunocytochemistry, cells were fixed in 4% paraformaldehyde (Affymetrix) 
at room temperature, permeabilized with 0.01% Triton X for 5 min, then blocked in 10% 
goat serum before staining with the following primary antibodies overnight: rabbit anti-
hERG polyclonal (Santa Cruz sc-20130, 1:50) and mouse IgG2b anti-cardiac troponin I 
(US Biological T8665-13F, 1:200). Corresponding secondary antibodies used were: goat 
anti-rabbit IgG Alexa Fluor 488 and goat anti-mouse IgG2b Alexa Fluor 633 
(ThermoFisher, 1:200). The nuclei were stained with 3 μM DAPI (Sigma-Aldrich). Images 
were taken with a Zeiss LSM 510 Meta confocal microscope with a 63x objective. 
3.2.3 Optical mapping 
Monolayers were stained with 10 μM di-4-ANEPPS (ThermoFisher) for 10 min at 
37°C in Tyrode’s solution before transfer to a heated stage for optical mapping. After 
staining, 10 μM blebbistatin (Sigma-Aldrich) was added to the Tyrode’s solution to inhibit 
motion artifact due to cell contraction. Optical action potentials were recorded with a 
MiCAM Ultima-L CMOS camera at 500 frames per second with tandem 1x macro lenses, 
providing a field of view of 1cm x 1cm and spatial resolution of 100 x 100 pixels. Electrical 
pacing was delivered through a pair of platinum electrodes placed immediately next to the 
edge of each monolayer. For drug tests, E-4031 (Tocris) or ML-T531 (a kind gift from Dr. 
Min Li at Johns Hopkins) were added to the mapping bath in sequential incremental 
concentrations, and action potentials were recorded 8 min after each concentration to allow 
sufficient time for the cardiomyocytes to respond to the drugs. 
Optical recordings were analyzed by custom MATLAB scripts. Briefly, optical 
action potentials were de-noised at each pixel by regulating the total variance in the signal 
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using a previously described method (Little and Jones, 2010) and convolved with a 5×5 
spatial Gaussian filter. The border of the coverslip was manually traced, and pixels outside 
the border were excluded from analysis. The derivative of membrane potential (dV/dt) was 
calculated as previously described (Chartrand, 2011), and then the activation time was 
found by the time of maximum dV/dt and was used to calculate local conduction velocity. 
Action potential durations were calculated as the time spent from upstroke to the time of 
the membrane voltage’s first return to a defined percentage towards resting potential (e.g., 
30% or 80% repolarization). 
3.2.4 Statistics 
Data are presented as mean±SD, with number of measurements (values of n) 
provided. The unpaired Student’s t-test was used to compare action potential and 
conduction velocity measurements between WT and LQT2-A422T monolayers. The paired 
t-test was used to compare the IQR-APD80 and conduction velocities before and after drug 
application. A significance level of p < 0.05 was used. 
3.3 Results 
3.3.1 Differentiation and syncytial culture of LQT2-A422T hiPSC-CMs 
Using a monolayer-based differentiation protocol (Boheler et al., 2014; Wang et al., 
2015), beating cardiomyocytes were obtained from both WT and LQT2-A422T hiPSCs. 
Beating areas were found in cultures as early as 7 days after initiating differentiation, and 
continued to develop with time. The percentage of cardiomyocytes from differentiation 
was verified by flow cytometry, which showed >95% cTnT positive cells that were 
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considered as cardiomyocytes (Fig. 3.1C) for both lines. There was no difference in 
differentiation efficiency between WT and LQT2-A422T hiPSCs. Dissociating and re-
plating the cardiomyocytes with trypsin resulted in evenly distributed monolayers of 
cardiomyocytes that beat spontaneously and regularly across the entire seeded area, with 
visible synchronized beating under phase contrast microscopy emerging  a few days after 
re-plating. These monolayers were stable in culture for at least 60 days. 
3.3.2 Molecular biological characteristics 
To confirm the disease genotype in the LQT2-A422T hiPSCs, Sanger sequencing 
of the KCNH2 gene was performed around the expected mutation site for both WT and 
LQT2-A422T hiPSC-CMs. The result confirmed the presence of a heterozygous single 
nucleotide mutation G1264A in the LQT2-A442T line, leading to a single amino acid 
substitution (A422T) in hERG (Fig. 3.1A). This missense mutation was not found in WT 
hiPSCs. Furthermore, RT-PCR of KCNH2 found both wild type and mutant mRNA in 
LQT2-A422T cardiomyocytes, indicating both alleles were actively transcribed. On the 
other hand, mutant mRNA was absent in WT cardiomyocytes (Fig. 3.1B), consistent with 
its labeled WT phenotype. At the protein level, western blots of hERG revealed a single 
band at around 110 kDa for both WT and LQT2-A422T cardiomyocytes (Fig. 3.1D); 
however, the relative amount of hERG was less in LQT2-A422T than in WT 
cardiomyocytes. Proteinase K treatment before protein extraction eliminated the hERG 
band in both WT and LQT2-A422T cardiomyocytes, indicating the hERG protein was 
accessible to proteinase K and thus likely bound to the cell membrane. In contrast to 
findings in HEK 293 cells, there was no distinguishable separation in hERG bands that 
would correspond to different glycosylation levels of the protein. Immunostaining of 
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hiPSC-CMs was also performed to study localization of the hERG protein in WT and 
LQT2-A422T cardiomyocytes (Fig. 3.1E). In WT cardiomyocytes (as labeled by cardiac 
troponin I, cTnI), hERG was evenly distributed throughout the cell, without significant 
perinuclear localization. On the other hand, in LQT2-A422T cardiomyocytes, some 
perinuclear hERG was also present, suggesting a potential trafficking defect, which is 
consistent with previous heterologous studies (Guo et al., 2012). However, there was also 
a significant amount of membrane-bound hERG in LQT2-A422T cardiomyocytes, which 
suggests that successful hERG trafficking was present in these mutant cardiomyocytes, and 
that the hERG protein may form function potassium channels in the membrane. 
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Figure 3.1 Molecular biological characteristics of LQT2-A422T hiPSC-CM. (A) DNA 
sequencing showing heterozygous mutation in KCNH2 gene. (B) RT-PCR confirms the 
presence of only WT mRNA in WT cardiomyocytes, while both WT and mutant mRNA 
are present in LQT2-A422T cardiomyocytes. (C) Flow cytometry of WT and LQT2-
A422T differentiation, showing >95% cTnT positive cells. (D) Western blot of hERG in 
WT and LQT2-A422T hiPSC-CMs. Proteinase K was used to confirm membrane 
localization of detected hERG band. (E) Immunostaining of WT (top row) and LQT2-
A422T (bottom row) monolayer. 
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3.3.3 Syncytial properties of hiPSC-CM monolayers 
Both WT and LQT2-A422T monolayers could support smoothly propagating 
action potentials, suggesting a functional syncytium. A pair of platinum electrodes was 
positioned just next to the monolayer to deliver electrical stimuli at a 1000 ms cycle length 
(CL), and the pacing was always able to initiate waves of action potentials that propagated 
across the entire area, as shown in the spatial maps of activation times (Fig. 3.2A-B). The 
smooth activation patterns indicate that the entire monolayer was electrically coupled, 
without conduction block. At 1000 ms CL, the average conduction velocities (CVs) were 
12.1±3.4 cm/s and 12.4±6.7 cm/s for WT and LQT monolayers, respectively, and did not 
differ significantly (Fig. 3.2C). Consistent with the LQT2 genotype, action potentials of 
LQT2-A422T monolayers were in general longer than those of WT monolayers (Fig. 
3.2D). The action potential duration measured at 80% repolarization (APD80) for LQT2 
monolayers was 416±66 ms, which was significantly longer than 291±19 ms for WT 
monolayers (Fig. 3.2E). The prolonged APD was mainly due to the longer plateau phase 
of the action potential, as indicated by the prolonged AP duration at 30% repolarization 
(APD30) for LQT2 monolayers compared with WT monolayers (310±63 ms vs. 170±23 
ms, respectively, Fig. 3.2F), rather than the rapid repolarization phase, as measured by 
triangulation (time from APD30 to APD80), which was in fact slightly shorter in LQT2 
monolayers than in WT monolayers (105±6 ms vs 121±17 ms, Fig. 3.2G). 
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Figure 3.2 Syncytial properties of hiPSC-CM monolayers. (A-B) Activation map of 
representative WT and LQT2 monolayers when electrically stimulated at 1000 ms cycle 
length. Blue indicates early activation, red indicates late activation. Isochrones have 10 ms 
spacing. (C) Conduction velocity measured in WT and LQT2 monolayers. (D) Comparison 
of average action potentials across entire WT or LQT2 monolayers. (E-G) Comparison of 
action potential parameters between WT and LQT2 monolayers. (C, E-G) n=6 for WT 
monolayers and n=8 for LQT2 monolayers  
The use of a cm-sized syncytial model enabled comparison of action potentials 
recorded from many different sites within the monolayer. An example is shown in Fig. 3.3. 
Within a single monolayer, there was some variability in action potential shapes, as shown 
in Fig. 3.3A, where the solid line indicates the average action potential for that monolayer, 
and lighter traces indicate the superimposed APs recorded from individual sites across the 
monolayer. APs across the monolayer generally had the same overall morphology of the 
average AP for the monolayer, with no significant variation observed. This is in sharp 
contrast to action potentials recorded from single cells, where much larger variability in 
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AP morphology is usually observed and often categorized into nodal-like, atrial-like and 
ventricular-like subtypes by their action potential shapes. Action potential durations are 
usually among the criteria used for subtype classification. Therefore, APD80 and APD30 
from individual recording sites were also calculated, and their distributions are shown in 
Fig. 3.3B. Comparing the blue cluster of a representative WT monolayer and the red cluster 
of an LQT2 monolayer, there was a clear phenotypic difference between the two, as the 
two clusters occupied separate, distinct areas in the AP parameter space. The distributions 
of APD30 (vertical) and APD80 (horizontal) in the margins suggest a similar conclusion, 
with the LQT monolayer having longer APDs at both repolarization levels. The spreads 
within both the WT (blue) cluster and LQT2 (red) cluster were much smaller than the 
differences between the means (indicated by the white dots). This is also represented in the 
separated histograms for both APD80 and APD30, where a single, Gaussian-like distribution 
was observed for each monolayer. The spread in AP morphology presumably reflects 
biological variability inherent to the hiPSC-CMs, but the tightness of the APD80 and APD30 
distributions suggests there is only one phenotype within the monolayer as discussed in 
Chapter 2. The tightness of distributions within each monolayer was quantified by average 
IQR-APD80 values for WT and LQT2 monolayers were 27.6±11.2 and 23.0±7.6 ms, 
respectively, and were not significantly different (Fig. 3.3C). As commented earlier, these 
were much smaller than the difference between the mean APD80s (125±69 ms). 
Further, how cells with different AP characteristics are spatially distributed within 
a monolayer was studied. The spatial maps of APD80 of representative WT and LQT2 
monolayers are shown in Fig. 3.3D-E, respectively. Overall, there was a tendency for cells 
with similar APD80 to cluster within proximity of each other (n = 6 WT monolayers and n 
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= 8 LQT2 monolayers), rather than being distributed in an intermixed pattern (none 
observed). This local grouping phenomenon suggests that environmental factors, such as 
bioelectrical, biomechanical and biochemical signals, may cause cells in proximity to 
develop similar electrophysiological properties, even for disease hiPSC-CMs, as discussed 
in Chapter 2. 
 
Figure 3.3 Variability in WT and LQT2 monolayers. (A) Action potential variability in 
representative WT (blue) and LQT2 (red) monolayers. Solid lines are average action 
potential of the monolayer. Shaded areas indicate overlay of action potentials recorded 
from individual sites within the monolayer (n=6679 for WT and n=6101 for LQT2). (B) 
APD80 and APD30 distributions of WT and LQT2 monolayers. (C) Comparison of IQR-
APD80, a measurement of APD80 variability, between WT (n=6) and LQT2 (n=8) 
monolayers. (D-E) Spatial map of APD80 in representative WT and LQT2 monolayers. 
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3.3.4 Response of WT and LQT2 monolayers to IKr blockade with E-4031 
The A422T mutation in hERG has been shown in HEK 293 cells to impair the rapid 
component of the delayed outward potassium current (IKr). Since immunofluorescence data 
suggests membrane-bound hERG exists in the heterozygous LQT2-A422T hiPSC-CMs 
(Fig. 3.1E), additional IKr blockade experiments were conducted. E-4031 (a specific IKr 
blocker) was applied to LQT2-A422T monolayers, which led to a concentration-dependent 
prolongation of action potential (Fig. 3.4A), confirming the presence of functional IKr in 
LQT2 monolayers. Furthermore, E-4031 led to loss of excitability in LQT2 monolayers at 
20 nM concentration for all 5 samples tested, and at 10 nM for 3 among them, which 
suggests that IKr assists in the maintenance of resting potential and sodium current 
availability necessary for excitation. On the other hand, WT monolayers retained 
excitability with IKr blockade by E-4031 at a much higher concentration, up to the highest 
concentration tested (100 nM). Similar to LQT2 monolayers, WT monolayers also showed 
a concentration-dependent prolongation in action potentials with increasing E-4031 (Fig. 
3.4B), but the concentration required to elicit a given amount of AP prolongation was much 
higher than that required for LQT monolayers. The concentration responses to E-4031 in 
terms of APD80 (a measure of the overall action potential duration), APD30 (a measure of 
the plateau phase duration) and triangulation (a measure of the rapid repolarization phase 
duration) are shown in Fig. 3.4 C-E, where LQT2 monolayers demonstrated a higher 
sensitivity to E-4031 compared to WT monolayers, as shown by the left-shifted response 
curves. Furthermore, IKr blockade prolonged the plateau and rapid repolarization phases of 
the action potential in LQT2 monolayers as evident by simultaneously increased APD30, 
APD80 and triangulation. But in WT monolayers its effect was mostly on the rapid 
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repolarization phase, with a more marked increase in APD80 and triangulation than in 
APD30. 
 
Figure 3.4 Monolayer response to IKr blockade by E-4031. (A) Average action 
potentials across an LQT2 monolayer in response to 0-10 nM E-4031. (B) Average action 
potentials across a WT monolayer in response to 0-100 nM E-4031. (C-E) Concentration-
dependent APD80 (C), APD30 (D) and Triangulation (E) responses to E-4031 in LQT2 (n=5 
for 1 nM and 2 nM, n=2 for 10 nM) and WT (n=3) monolayers. Error bars indicate standard 
deviation. 
3.3.5 Response of WT and LQT2 monolayers to IKr activation with ML-T531 
Next, the hypothesis that IKr can normalize action potentials in LQT2-A422T 
monolayers was tested. ML-T531 is an IKr activator that enhances the current by reducing 
the voltage sensitivity of inactivation, and has been shown to normalize action potentials 
in LQT1 (reduced IKs) hiPSC-CMs (Zhang et al., 2012). With ML-T531, APs recorded 
from LQT2 monolayers showed a concentration-dependent shortening (Fig. 3.5A). At 10 
μM (highest concentration tested), an elevated membrane potential at the end of rapid 
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repolarization was also observed, before slowly returning to baseline (Fig. 3.5A, arrow) 
which may indicate an increased risk of ectopic activity. On the other hand, ML-T531 did 
not significantly shorten the action potentials of WT monolayers (Fig. 3.5B), possibly 
because of the relatively short plateau phase, which is where ML-T531 would have been 
most effective by keeping IKr from becoming inactivated. Measurements of AP durations 
are also consistent with the waveform observations. ML-T531 significantly shortened 
APD80 in LQT2 but not WT monolayers (Fig. 3.5C), which was mainly the result of 
shortened plateau (as measured by APD30, Fig. 3.5D) rather than of more rapid 
repolarization (as measured by triangulation, Fig. 3.5E). Indeed, 6 μM of ML-T531 
shortened APs in LQT2-A422T monolayers to a level comparable to that of WT 
monolayers. Furthermore, a representative activation map showed that in the presence of 
ML-T531 the monolayer still supported smooth AP propagation (Fig. 3.5F), which was 
also observed in two other LQT2 monolayers tested. ML-T531 also led to an increase in 
conduction velocity in LQT2 monolayers at 10 μM concentration (p=0.002, n=3), which 
may be a result of a greater percentage recovery of excitability due to the increased diastolic 
interval at the constant 1000 ms cycle length (Fig. 3.5 G). 
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Figure 3.5 Monolayer response to IKr activation by ML-T531. (A) Average action 
potentials across an LQT2 monolayer in response to 0-10 μM ML-T531. (B) Average 
action potentials across a WT monolayer in response to 0-10 μM ML-T531. (C-E) 
Concentration-dependent response of APD80 (C), APD30 (D) and Triangulation (E) to ML-
T531 in LQT2 and WT monolayers. Error bars indicate standard deviation. (F) Activation 
times in a representative LQT2 monolayer with ML-T531. (G) Conduction velocity 
response to ML-T531 in WT and LQT2 monolayers. (C-E,G) n=3 each for LQT2 and WT. 
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3.3.6 Dependency of drug response to baseline action potential duration 
Next, the effect of IKr blockade and activation on action potential variability was 
investigated. The APD80 histograms at different E-4031 concentrations for a representative 
LQT2 monolayer are shown in Fig. 3.6A-a. The AP variability (IQR-APD80) was not 
significantly affected by 1 nM E-4031 for this and 4 other monolayers tested (97%±11% 
of baseline, n=5), but at 10 nM, it increased to 170% and 188% of baseline values for this 
and one other monolayer that remained excitable, respectively. On the other hand, the 
APD80 histograms at different E-4031 concentrations for a representative WT monolayer 
are shown in Fig. 3.6A-b. At both 10 nM and 100 nM, IQR-APD80 was not significantly 
affected for this and other 2 monolayers tested (111%±29% and 116%±35% of baseline, 
respectively, n=3). 
Since the AP-shortening effect by ML-T531 was most prominent during the plateau 
phase rather than the rapid repolarization phase (Fig. 3.5 C-E), APD30 was used instead of 
APD80 for studying the effect of ML-T531 on action potential variability. The APD30 
histograms are shown for a representative LQT2 monolayer in Fig. 3.6B-a, and for a 
representative WT monolayer in Fig. 3.6B-b. The spread of APD30 for LQT2 was 
decreased by 10 μM ML-T531 (IQR-APD30 was reduced to 50%±5% of baseline), but 
stayed roughly the same for WT (IQR-APD30 was 99%±32% of baseline). 
Next, how IKr blockade and activation can affect action potential variability was 
investigated. Fig. 3.6C shows the response to E-4031 of cells having similar baseline 
APD80, using the LQT2 monolayer of Fig. 3.6A-a as an example. The gray histogram in 
Fig. 3.6C-a shows the APD80 distribution within the monolayer. The black bar indicates a 
subpopulation of cells having similar baseline APD80. Application of 1 nM E-4031 caused 
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a general right-shift of the histogram for this monolayer, as shown in the light blue 
histogram in Fig. 3.6C-b. The subpopulation cells with similar baseline APD80 responded 
differently to 1 nM E-4031, as indicated by the solid blue histogram contained within the 
light blue histogram. The grey lines connecting Fig. 3.6C-a and b indicate the range of 
post-drug APD80 for this subpopulation. The differences between each cell represented in 
the blue and black histogram is their corresponding responses to 1 nM E-4031, as 
quantified by ΔAPD80. The variable responses of cells having similar baseline APD80 can 
potentially increase variability.  
The process of calculating ΔAPD80 was repeated for all cells in the example LQT2 
and WT monolayers shown in Fig. 3.6A, and the results are shown in Fig. 3.6D (D-a for 
LQT2 and D-b for WT) as the dependency of E-4031 blockade (shown as drug-induced 
increase of APD80) on pre-drug APD80. In general, there was a consistent negative 
dependence of APD80 prolongation (ΔAPD80) on baseline (pre-drug) APD80 in LQT2 
monolayers with 1 nM E-4031, where the prolongation of APD80 was larger in regions with 
shorter baseline APD80 than in regions with longer baseline APD80. This negative APD80 
dependency disappeared when E-4031 concentration was increased to 10 nM. Instead, the 
drug response became highly variable independent of the baseline APD80, which was 
accompanied by a wider spread in the ΔAPD80 histogram (compare the red to the blue 
histogram in the vertical margin of the graph. Fig. 3.6D-a). When linear regression was 
applied to analyze the ΔAPD80 dependency on baseline APD80, a negative slope was found 
for both 1 nM and 10 nM E-4031, as indicated by the dashed lines in Fig. 3.6D-a. However, 
the R-squared values decreased with increased E-4031 concentration (from 0.45 to 0.09 in 
this example), indicating increased variance not explained by the negative baseline APD80 
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dependency. WT monolayers also showed a consistently negative APD80 dependence of 
APD80 prolongation over all E-4031 concentrations tested. There was some variability in 
E-4031 response within regions of similar baseline APD80, but the spread in the ΔAPD80 
histogram was not affected by the higher drug concentration (Fig. 3.6D-b). This is also 
evident by the negative slope found in the linear regression (dashed lines in Fig. 3.6D-b). 
In fact, the R-squared values increased with increased E-4031 concentration (from 0.29 to 
0.50) in this example. The negative APD80-dependency on baseline APD80 observed here 
can potentially decrease variability. 
APD30 was used instead of APD80 for studying the monolayer response to ML-
T531, and the ΔAPD30-dependency on baseline APD30 is shown in Fig. 3.6E (E-a for the 
example LQT2 monolayer in Fig. 3.6B-a and E-b for the example WT monolayer in Fig. 
3.6B-b). A strong negative APD30-dependency of ΔAPD30 was observed at 10 μM ML-
T531 for LQT2 monolayers, with a weaker negative APD30-dependency at 3 μM ML-T531 
for LQT2 monolayers and at both 3 μM and 10 μM ML-T531 for WT monolayers. In all 
these monolayers, recording sites with longer baseline APD30 tend to be shortened more 
by the drug than sites with shorter baseline APD30.  This is also represented in the example 
shown in Fig. 3.6E by the steeper slope (-0.69) of the linear regression of LQT2 at 10 μM 
compared to the other conditions (-0.24 for LQT2 at 3 μM, -0.23 for WT at 3 μM and -0.25 
for WT at 10 μM). The R-squared values increased in the LQT2 example from 0.26 at 3 
μM to 0.67 at 10 μM, and slightly decreased in the WT example from 0.16 at 3 μM to 0.13 
at 10 μM. Like the APD80-dependency on baseline APD80 described for E-4031 response, 




Figure 3.6 Action potential variability in response to IKr blockade or activation. (A) 
APD80 histograms at baseline or with E-4031 for representative LQT2 (a) and WT (b) 
monolayers.  (B) APD30 histograms at baseline or with ML-T531 for representative LQT2 
(a) and WT (b) monolayers. (C) Illustration of ΔAPD80 calculation. (a) baseline APD80 
histogram of the LQT2 monolayer of A-a, with the solid black bar highlighting the cells 
with baseline APD80 falling within a 2 ms-wide bin centered at 392 ms. (b) APD80 
histogram of this monolayer with 1 nM E-4031. The cells represented within black bar in 
C-a became the dark blue histogram contained in the larger, light blue histogram. ΔAPD80 
is calculated for each cell in the black bar as the difference between APD80 at baseline and 
with the cell’s corresponding point in the dark blue histogram, as indicated in the figure. 
(D) ΔAPD80-dependence on baseline APD80 for representative LQT2 (a) and WT (b) 
monolayers in response to E-4031. (E) ΔAPD30-dependence on baseline APD30 for 
representative LQT2 (a) and WT (b) monolayers in response to ML-T531. (D,E) Dashed 
lines are linear regression fits of the scatter plots. 
3.3.7 Electrophysiological abnormality in LQT2-A422T monolayers 
The two-dimensional cell monolayer provides a substrate in which complex 
patterns of propagation can occur. Conduction heterogeneity and conduction block are 
among the most important factors that promote the induction and maintenance of reentrant 
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arrhythmia. In LQT2-A422T monolayers, conduction heterogeneity and conduction block 
can be induced by several methods, including premature pacing and hypoxia. 
 
Figure 3.7 Example of conduction heterogeneity in LQT2 monolayers. (A) Activation 
snapshot during baseline pacing at 1000 ms cycle length (a) and corresponding activation 
map (b). (B) Activation snapshot immediately following a 450 ms interval premature 
stimulus (a) and corresponding activation map (b). In activation snapshots red indicates 
depolarized regions, blue indicates resting regions. In activation maps isochrones have 10 
ms spacing. (C) Action potentials recorded from three different locations on the monolayer, 
as indicated in A-a and B-a. Bottom trace shows the electrical stimulus pulses. Arrow 
indicates the premature pacing-induced subthreshold activity at site 3. 
The effect of premature pacing is shown in Fig. 3.7. At baseline, 1000 ms cycle 
length pacing always initiated propagating action potentials across the monolayer, as 
shown in the membrane potential snapshot (Fig. 3.7A-a) and activation map (Fig. 3.7A-b). 
When a premature stimulus was applied at 450 ms interval following a baseline paced 
stimulus pulse, the action potential was only able to propagate to one side of the pacing 
electrode (to the right-hand side in Fig. 3.7B-a, with a complete conduction block on the 
left-hand side). The activation map had a curved AP propagation pattern (Fig. 3.7B-b), 
which is a precursor to spiral wave formation. The conduction velocity was also slower, 
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due to the shorter diastolic interval and wavefront curvature. The presence of conduction 
block produced by the premature stimulus is also evident in the individual action potential 
traces recorded from different sites in the monolayer (Fig. 3.7C), corresponding to the 
numbered sites shown in Fig. 3.7 A-a and B-a. In site 1, to the right of the pacing site, 
premature pacing elicited an action potential that propagated to site 2. In site 3, to the left 
of the pacing site, premature pacing only triggered a sub-threshold response (arrow), and 
an action potential was later initiated by propagation from site 2. This example 
demonstrates that a monolayer model can be created from LQT2 hiPSC-CMs that 
manifests conduction heterogeneity created by temporal, dynamic pacing. 
 
Figure 3.8 Hypoxia-induced variability in LQT2-A422T monolayer. (A) Baseline. (B) 
Monolayer partially covered by a circular glass coverslip (approximate location of edge 
indicated by white dashed line in B-a,b) for 20 min to induce a hypoxic condition. For both 
baseline and hypoxic conditions: (a) Activation pattern. Isochrones are 10 ms apart. Note 
the alteration in conduction pattern induced by the coverslip. (b) APD80 map. (c) APD80 
histogram for the entire monolayer. 
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In addition to dynamic pacing, cellular heterogeneity can also be produced by 
blocking access of part of the monolayer to the bath solution by a glass coverslip as has 
been demonstrated previously in neonatal rat myocyte monolayers (de Diego et al., 2008; 
Pitts and Toombs, 2004). The coverslip creates an acute hypoxic condition, as shown in 
Fig. 3.8. This LQT2-A422T monolayer at baseline was able to support smoothly 
propagating action potentials (Fig. 3.8A-a), and the action potential characteristics were 
also relatively homogeneous, as indicated by the APD80 map (Fig. 3.8A-b) and single peak 
in the APD80 histogram (Fig. 3.8A-c). When a glass coverslip was placed on top of a 
portion of the monolayer (Fig. 3.8B-a), the area underneath the coverslip (bounded by the 
dashed white line) became hypoxic, which led to slowing of conduction and a complex 
activation pattern. Action potential variability increased as result of the hypoxic condition. 
Action potentials in the region located underneath the coverslip became shorter, potentially 
as a result of the opening of the ATP-sensitive potassium channel (IK,ATP) in response to 
the hypoxic condition, while action potentials in the region surrounding the coverslip 
became longer, which could be an effect secondary to the slowed conduction and reduced 
excitability in the adjacent region underneath the coverslip (Fig. 3.8B-b). The overall 




Figure 3.9 Arrhythmic event in LQT2-A422T monolayers. (A) Spontaneously formed 
spiral wave anchored to the center of a 35 mm diameter monolayer. a. Activation snapshot. 
White arrows indicate direction of spiral wave propagation. Blue indicates resting tissue; 
red indicates activated tissue. b. activation time map shows the core of the spiral wave. 
Activation isochones are 50 ms apart. Scale bars in a and b are 1mm. c. Action potential 
traces recorded within the monolayer, corresponding to the same numbered sites in a. Scale 
bar is 100 ms. (B) Ectopic activity in 6 mm diameter monolayer.  a. activation snapshots 
at different time points corresponding to labels in b, specifically: 1. Propagation of a 
spontaneous action potential originating from a site at the edge of the monolayer. 2. Just 
before EAD. 3. Peak of EAD. 4. At rest. b. Action potentials averaged across the entire 6 
mm monolayer paced at 1000 ms cycle length at baseline, or spontaneous with 100 nM E-
4031. Spontaneous EAD occurred in the presence of E-4031, as indicated by the arrow. 
Further, the size of the monolayer can influence the electrophysiological behavior 
of the monolayer. In a large, 35 mm diameter LQT2 monolayer, a spiral wave formed 
spontaneously (Fig. 3.9A). In this case, application of ML-T531 abbreviated the action 
potentials but was not able to terminate the reentrant activity (not shown). On the other 
hand, EADs were inducible in smaller, 6 mm diameter monolayers (3 out of 4 total), by IKr 
blockade with 100 nM E-4031 (Fig. 3.9B). A spontaneous action potential originated from 
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the edge of the monolayer and propagated across the monolayer (Fig. 3.9B-a, time point 
1). The entire monolayer then repolarized by approximately by 50% (Fig. 3.9B-a, time 
point 2), just prior to the occurrence of an EAD. The EAD then occurred, affecting the 
entire monolayer and slightly depolarizing the membrane potential before returning to rest 
(Fig. 3.9B-a, time points 3-4). The average action potentials of this small monolayer at 
baseline and with E-4031 are shown in Fig. 3.9B-b. Note that E-4031 dramatically 
prolonged the action potential to have a duration of more than 3 sec. The significantly 
prolonged period at a depolarized membrane potential provided the necessary condition 
for EAD formation. 
3.4 Discussion 
The electrophysiological characteristic of LQTS is a prolonged QT interval in the 
ECG, which is the result of action potential prolongation at the cellular level. 
Cardiomyocytes derived from LQTS patients have been shown to recapitulate this key 
characteristic (Bellin et al., 2013; Lahti et al., 2012; Matsa et al., 2011; Mehta et al., 2014b; 
Spencer et al., 2014). The results shown here in the monolayer model are consistent with 
these prior findings, with markedly prolonged APs in LQT2-A422T monolayers compared 
to those in WT monolayers (Fig. 3.2). The morphological changes in action potential 
observed here are also similar to those previously reported, where LQT2 cardiomyocytes 
generally have a more prominent plateau in their APs, despite differences in specific 
mutations in KCNH2 (Lahti et al., 2012; Matsa et al., 2011; Mehta et al., 2014b). Patch 
clamp recordings of APs in LQT2 hiPSC-CMs suggest three major cardiac phenotypes, 
similar to the observations of non-diseased hiPSC-CMs. However, a prolonged AP was 
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most consistently observed in ventricular-like cardiomyocytes (Lahti et al., 2012; Matsa et 
al., 2011; Mehta et al., 2014b), not always in atrial-like cardiomyocytes (or even absent 
(Lahti et al., 2012)), and not in pacemaker-like cardiomyocytes (Matsa et al., 2011). In 
contrast, I have shown in Chapter 2 that cell monolayers promote a single phenotype in 
hPSC-CMs. The observations with LQT2-A422T hiPSC-CMs of a single LQT2 phenotype 
also support this finding. Here, the single phenotype is ventricular-like with prolonged 
action potential duration, which is the characteristic electrophysiological feature of LQTS. 
As discussed in Chapter 2, the reduced variability in AP duration and morphology is likely 
to be a combined result of cell-cell interactions through bioelectrical, biochemical and 
biomechanical pathways. This is very different from observations from patch clamp studies, 
where varying action potential morphologies are observed and empirically identified as 
different subtypes, and where the prolongation in action potentials  is also absent in some 
subtypes. The promotion of a single phenotype in the monolayer model can result in more 
consistency in terms of studying cardiac diseases like LQT2. 
Spontaneous arrhythmic activity is frequently observed in single cell 
electrophysiological recordings of LQT2 hiPSC-CMs, usually as EADs. A previous study 
on hiPSC derived cardiomyocytes carrying the same LQT2-A422T mutation showed that 
small clusters of diseased hiPSC-CMs had markedly prolonged action potentials and 
spontaneous EADs that were closely correlated with their Ca2+ transients, demonstrating a 
possible mechanism of arrhythmia (Spencer et al., 2014). Interestingly, this ectopic activity 
was not observed in the 10 mm monolayers of this study (Fig. 3.4A), which resembled a 
much milder LQT2 phenotype. However, stressing the 10 mm LQT2 monolayers further 
with E-4031 revealed an elevated sensitivity to IKr blockade compared to WT monolayers 
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(Fig. 3.4A,B), consistent with previous observations of the LQT2 hiPSC-CM phenotype 
(Matsa et al., 2011), although EADs were still absent in this study. It was only when the 
size of the monolayers was reduced to 6 mm, and with IKr blockade, that EADs were 
observed (Fig. 3.9). The reduced-dimension monolayers are closer to, although still much 
larger than the small clusters used in previous studies with MEAs (Lahti et al., 2012; Matsa 
et al., 2011; Mehta et al., 2014a). Taken together, these observations suggest the dimension 
of syncytial cultures may affect the stability and occurrence of ectopic activity in hiPSC-
CMs. It is worth pointing out that despite being significantly higher than in healthy adults, 
the occurrence of cardiac events in LQTS patients is still rare in absolute measures (Kim 
et al., 2010b). Thus, the absence of EADs in cm-sized syncytial monolayers may indeed 
be a manifestation more similar to the patient situation. 
The mechanism of the hERG-A422T mutation affecting hERG current was first 
studied in heterologous expression systems using HEK 293 cells (Guo et al., 2012; Sharma 
et al., 2004). Like many other mutations in the KCNH2 gene, as reviewed in (Smith et al., 
2016), A422T has been shown to lead to marked reduction of IKr by causing a hERG 
trafficking defect, and exert dominant-negative suppression of WT protein. The 
immunofluorescence data in this study are consistent with this mechanism, in that 
perinuclear hERG was observed in LQT2-A422T but not in WT cardiomyocytes (Fig. 
3.1E). However, membrane-bound hERG expression was also found in both WT and 
LQT2-A422T cardiomyocytes. This is probably a manifestation at the protein level of the 
mutation being heterozygous in the LQT2-A422T hiPSC line, and suggests that, at 
physiological expression levels in a cardiomyocyte, not all hERG proteins are affected by 
the trafficking defect. Other evidence of membrane-bound hERG expression includes the 
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protease K-sensitive band in western blots (Fig 3.1D). Some earlier reports of LQT2 
hiPSC-CMs carrying different KCNH2 mutations reported two hERG bands in western 
blots, indicative of different levels of glycosylation and therefore a possible trafficking 
defect (Bellin et al., 2013; Mehta et al., 2014b), but in this study only a single band was 
observed. 
Methods to rescue diseased phenotypes can also be evaluated using patient-specific 
hiPSC-CMs. For LQTS, widely adopted strategies based on the mechanism of the disease 
include: 1) β-blockers, which has high efficacy in LQT1 patients, by reducing ectopic 
events that could lead to arrhythmia during exercise; 2) pharmacological strategy that 
compensates for the abnormal function of the mutant channel, thereby restoring balance in 
ion currents and normalizing action potentials, and 3) specifically for trafficking defects, 
chemical chaperones that stabilize the mutant protein and facilitate trafficking to restore 
normal channel expression (Ruan et al., 2008). The membrane-bound hERG found in 
immunostaining, as well as E-4031-induced AP prolongation suggests the presence of 
functional IKr in LQT2-A422T monolayers, making pharmacological IKr activation a viable 
strategy to be tested. The ML-T531 used in this study is an IKr activator that enhances IKr 
by reducing the voltage sensitivity of channel inactivation during an action potential. It has 
been shown previously to normalize action potentials in LQT1 (KCNQ1 mutation) hiPSC-
CMs (Zhang et al., 2012). Application of ML-T531 was sufficient to normalize action 
potentials in the present LQT2-A422T model (Fig. 3.5A), supporting the notion that 
functional hERG is present at the cell membrane. The ectopic activity induced by a high 
concentration of ML-T531 indicates the presence of a net inward current towards the end 
of the action potential, which could be a result of an overly shortened action potential 
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duration, where outward IKr inactivates near the resting potential regardless of the presence 
of ML-T531, while inward currents such as ICaL or INaCa may still persist. A similar 
observation of an afterdepolarization in the presence of a different IKr enhancer has been 
reported in a different LQT2 hiPSC-CM model (Matsa et al., 2011), although in that study 
beta-adrenergic stimulation was also required. 
To date, electrophysiology studies using hiPSC-CMs have been predominately 
performed with isolated cardiomyocytes and patch clamp. These cellular-level models are 
valuable in understanding single cell electrophysiology and the triggers of arrhythmia 
events, such as EADs. Small clusters of cells have also been used where their 
electrophysiology was recorded with MEAs in the form of field potentials (FPs). While it 
has been shown that FPs are correlated to APs, especially with respect to their durations 
(Halbach et al., 2003), and it is possible to mathematically relate FPs to APs (Tertoolen et 
al., 2017), they are still indirect measures of the APs. Due to the increased complexity in 
circuit design with the fabrication of an increased number of electrodes, a typical MEA 
system is limited to approximately 60 electrodes and is usually recording from a much 
smaller area (around 1mm × 1mm) than the areas that were optically mapped in the 
monolayers studied in this chapter. While MEAs do record electrophysiological activities 
from small groups of cardiomyocytes that are considered to form a functional syncytium, 
the small dimension greatly limits the measurements of tissue-level properties such as 
conduction velocity. The smaller dimension models also cannot sustain reentrant 
arrhythmia, which therefore limits their application in studying the maintenance of an 
arrhythmia event. 
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High resolution optical mapping enables simultaneous recordings of action 
potentials of large hiPSC-CM populations across much larger syncytial areas than those 
studied with MEAs. This enables the study of variability in electrophysiology that can 
favor drug- and disease-induced arrhythmias. One example explored in this study was 
variability in cellular responses to IKr blockade and its dependency on baseline 
electrophysiology. In general, a negative APD80-dependency was observed with E-4031 in 
both WT and LQT2 monolayers, indicating that cells with shorter baseline AP were 
affected more by IKr blockade (Fig. 3.6A). This is presumably because those cells had more 
IKr than cells with longer baseline APs, and therefore would respond more strongly. Such 
a negative APD80-dependency can potentially reduce overall AP variability. However, in 
LQT2-A422T monolayers this effect was masked by an additional overall increase in AP 
variability in response to the drug for cells having the same baseline APD80s, indicated by 
the reduction in the R-squared value of the linear fit of the APD80-dependency  (Fig. 3.6A-
a). Interestingly, this variability among cells with similar baseline APs increased with 
higher E-4031 concentration (Fig. 3.6A-a), up to the concentration where monolayers lost 
capture to electrical pacing. The increase in response variability led in turn to increased 
post-drug APD80 heterogeneity, which is a potentially proarrhythmia effect, despite the 
overall negative APD80-dependency which acts to reduce its variability.  
Negative APD-dependency at 30% repolarization (APD30-dependency) was also 
observed with ML-T531 in LQT2-A422T monolayers (Fig. 3.6C-a), where APD30 
shortening was smaller in regions with baseline APs having shorter plateaus than in regions 
with baseline APs having longer plateaus, an effect that again would reduce overall AP 
variability. This dependency was mostly absent in WT monolayers (Fig. 3.6C-b), due to 
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only minor shortening in APD by ML-T531. In LQT2-A422T monolayers, the negative 
APD30-dependency is consistent with the activation window of IKr current being at AP 
plateau voltages and is different from the strong APD80 dependency observed with E-4031 
(Fig. 3.6A-a). This difference can be explained by the different mechanisms of action of 
ML-T531 and E-4031. ML-T531 shifts the inactivation of IKr towards more positive 
voltages and slow inactivation (Zhang et al., 2012), thereby increasing IKr. The effect of 
enhanced IKr is more prominent during the earlier phase of the action potential where 
inactivation, rather than deactivation determines the availability of hERG channels, and is 
therefore captured by APD30, and indirectly by APD80 (Fig. 3.5C), but not by triangulation 
(Fig. 3.5E). On the other hand, E-4031 blocks IKr in its open state (Spector et al., 1996), 
which affects open channels during the entire duration of an action potential, thereby 
creating a long-lasting effect that is mainly captured by APD80. 
Furthermore, the ability to sustain propagating action potentials in the monolayer 
model allowed investigation of conduction and its relation to the mutation as well as drug 
treatment. Smooth propagation of action potentials was always observed in both WT and 
LQT2-A422T monolayers (Fig. 3.2A,B). There was qualitatively no change in conduction 
pattern observed with E-4031 or ML-T531 treatment, confirming the maintenance of a 
uniform syncytium. In the case of ML-T531, a lack of effect on conduction is important if 
it is to be considered as a rescuing strategy. ML-T531 did slightly increase CV in LQT2 
monolayers, but not in WT monolayers. This is perhaps a consequence of the shortening 
in action potential duration, which in turn shortens the refractory period, prolongs the 
diastolic interval and allows more time for recovery of excitability of the cardiomyocytes. 
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The experimentally-induced conduction heterogeneity demonstrated the capability 
of the 2D monolayer in studying induction and maintenance of reentrant arrhythmia in 
diseased models. Premature pacing induced a transient unidirectional block (Fig. 3.7B), 
which is well known to facilitate reentry (Quan and Rudy, 1990). The curved action 
potential wavefronts resulting from this unidirectional block further demonstrated the 
potential of reentry wave formation. Another example of conduction heterogeneity is by 
creating local hypoxia (Fig. 3.8). Acute hypoxia is known to shorten action potentials in 
cardiomyocytes through activation of ATP-sensitive K+ channels (Nichols et al., 1991). In 
the case of the LQT2-A422T monolayer, the action potentials became shorter with a slower 
upstroke (phase 0) in the region underneath the coverslip. Both of these conditions 
contributed to the heterogeneity in conduction that ultimately led to slowed and curved AP 
propagation. For future work, experimental approaches like this can be used to evaluate 
proarrhythmia risk in disease models. In addition to revealing arrhythmia triggers, the 
monolayer can also be used to quantify the risk in the syncytium for arrhythmia 
sustainability. 
Finally, reentry arrhythmia can spontaneously form in LQT2 monolayers, but a 
method to reliably induce arrhythmia in the monolayers was not determined in the current 
study. The spiral wave in the example shown in Fig. 3.9 was anchored to the center of the 
monolayer, which was likely a result of a local anatomical defect or local heterogeneity in 
the monolayer which facilitates spiral wave attachment (Lim et al., 2006), rather than a 
specific consequence of the LQT2 disease phenotype. Further, the conduction velocity of 
the spiral wave averaged across the entire observed area within the monolayer (1 cm × 1 
cm) was much slower than typically measured in monolayers without spontaneously 
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formed reentry, as indicated by the denser activation isochrones. This is in part due to fast 
activation at short cycle lengths, which reduces excitability and slows conduction, as well 
as the wavefront curvature (Fast and Kléber, 1997). The slow conduction can in turn, 
contribute to the maintenance of the spiral wave, which also warrants further investigation. 
In conclusion, syncytial monolayers of hiPSC-CMs are valuable in disease 
modeling. In the LQT2-A422T model discussed here, I have shown that the monolayer 
recapitulates key aspects of the disease phenotype and electrophysiology, and 
demonstrated that ML-T531 is a possible rescue strategy for this mutation. Tissue level 
properties, such as conduction velocity and population variability analysis, provided 





Chapter 4  
Predicting response to cardioactive drugs with 
hiPSC-CM monolayers 
4.1 Introduction 
Unexpected interaction with cardiomyocytes is the leading cause of removal of 
pharmaceutical agents from the market, for both cardiovascular and non-cardiovascular 
applications. There continues to be high demand for more accurate testing platforms for 
drug development. The current guidelines, ICH S7B for non-clinical and ICH E14 for 
clinical evaluation, were established in 2005 and before the discovery of hiPSCs. These 
current guidelines, as reviewed in Chapter 1.5, strongly rely on surrogate biomarkers such 
as interactions with hERG channels, or prolongation of the QT interval in the ECG, to 
predict the risk of drug-induced proarrhythmia. However, drug-induced proarrhythmia is 
the consequence of many factors combined, beyond the complexity of these surrogate 
biomarkers that only measure simple indices such as hERG channel blockade or QT 
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prolongation. In fact, these current biomarkers have been shown to be inadequate in 
performance (Gintant, 2011). Recently, the comprehensive in vitro proarrhythmia assay 
(CiPA) initiative has been proposed that combines heterologous expression systems, in 
silico simulation, hPSC derived cardiomyocytes and human ECG with the goal of 
developing an improved paradigm for assessing proarrhythmic risk (Colatsky et al., 2016). 
Cardiomyocytes derived from hPSCs are an invaluable resource for studying drug 
interactions in a human context, where the test compound can interact with major cardiac 
ion channels in a physiological context. Direct biomarkers related to drug-induced 
proarrhythmia, such as changes in beat rate, action potential duration and EAD formation, 
can be obtained, providing a more comprehensive assessment of proarrhythmia risk 
(Sinnecker et al., 2014). The use of hPSC-CMs for drug testing was introduced with hESC-
CMs (Braam et al., 2010; Caspi et al., 2009), but hiPSC-CMs provide additional benefits, 
including patient-specific and disease-specific drug responses. Well-established 
electrophysiological methods, such as MEA and patch clamp have been widely used in 
drug testing with hPSC-CMs (Braam and Mummery, 2010; Caspi et al., 2009; Tanaka et 
al., 2009). Other methods aimed at improving the accuracy and/or throughput of drug 
screening have also been reported, such as impedance-based assay (Peters et al., 2015), 
Kinetic image cytometry (Cerignoli et al., 2012) and microphysiological system (Mathur 
et al., 2015). A comparison with other pre-clinical assays showed that hiPSC-CMs in an 
MEA assay can identify similar effects as in rabbit ventricular wedge preparations for a 
panel of drugs (Harris et al., 2013), supporting their potential application for drug 
screening. However, single cell or small cluster models, while excellent in identifying 
drug-induced ectopic activities that could trigger an arrhythmia event, provide limited 
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insight on whether these triggered activities can become sustained arrhythmia. This 
limitation makes larger syncytial models, such as cell monolayers, desirable for their ability 
to model tissue-level properties.  
In Chapter 2, I have shown that monolayer culture promotes uniformity in the 
electrophysiological phenotype of hPSC-derived cardiomyocytes. The homogeneity in 
electrophysiology creates a consistent baseline for studying drug response within each 
monolayer. Further, monolayer-to-monolayer consistency was also found to be high in 
commercially available hiPSC-CMs, allowing the comparison of responses to different 
drugs across multiple monolayers. Here, as part of the CiPA phase 1 study, I present the 
response to cardioactive drugs of monolayers derived from commercially available Cor.4U 
hiPSC-CMs. The drugs and their respective concentrations were selected by the CiPA 
initiative, and include three categories: 1) specific ion channel blockers that selectively 
target a single ion current, including E-4031 (IKr), nifedipine (ICaL), mexiletine (INa) and 
JNJ303 (IKs); 2) mixed ion channel blockers that interact with multiple channels, including 
flecainide, quinidine and ranolazine; and 3) drug with off-target ion channel effect, which 
is moxifloxacin. The specific ion channel blockers suppress different major currents 
contributing to the cardiac action potentials, as noted above. Studying hiPSC-CM 
responses to these specific blockers can serve as positive controls to test the fidelity of an 
hiPSC-CM-based platform for drug screening. The mixed ion channel blockers include two 
class I antiarrhythmic agents (quinidine: class Ia and flecainide: class Ic) and one anti-
angina drug (ranolazine). These multi-activity drugs are used to study if a combination of 
effects are represented by different biomarkers that correspond to the different channel 
blockade effects. The drug with off-target effect, moxifloxacin, belongs to the family of 
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fluoroquinolone antibacterial agents and has a known QT-prolonging effect through 
blockade of hERG channels (Bischoff et al., 2000; Kang et al., 2001), and serves as an 
example of an hiPSC-CM-based platform being used to test non-cardiac drugs. In addition 
to action potential measurements, I also show monolayer responses to drugs in terms of 
tissue-level properties such as conduction velocity and action potential variability. 
Further, electrophysiological heterogeneity in the human heart plays an important 
role in maintaining normal cardiac function, and deviation from normal heterogeneity can 
be arrhythmogenic (Boukens et al., 2016). Optical mapping of the human heart wedge 
preparation has confirmed the presence of a transmural repolarization gradient that is a 
result of heterogeneity in action potential durations (Glukhov et al., 2010). Faithfully 
recapitulating this important electrophysiological property of the heart is especially 
beneficial for studying drug-induced proarrhythmic substrates, but is beyond the capability 
of a homogeneous cell monolayer. Computational simulations, on the other hand, provide 
a feasible alternative method to experiments for studying the variability of human 
cardiomyocyte populations. It has been demonstrated that biological variability can be 
represented in computational models of cardiomyocytes by introducing stochastic 
variables in the model’s parameter space, which in turn leads to variation in the model 
output (Britton et al., 2013; Johnstone et al., 2016; Sarkar et al., 2012). This 
electrophysiological variability also affects the response of simulated cardiomyocytes to 
channel blockade (Paci et al., 2016). At a tissue level, it has also been reported that an 
excitable biosynthetic model with inherent variability can simulate variability observed 
experimentally (Gokhale et al., 2017). In this chapter, I demonstrate the utility of 
heterogeneous populations of simulated hiPSC-CMs in drug testing. The simulations are 
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first conducted as an independent population of heterogeneous cells, where population 
variability in electrophysiology and its response to channel blockade are investigated. In 
addition, a heterogeneous monolayer is constructed computationally to simulate the 
electrophysiological heterogeneity found in human heart. The drug response is then studied 
in a tissue context with this defined heterogeneity. 
4.2 Methods 
4.2.1 Monolayer culture of Cor.4U cardiomyocyte and drug testing protocol 
The Cor.4U cardiomyocytes were obtained from Axiogenesis (Cologne, Germany) 
along with manufacturer-provided thawing medium and culture medium. Cells were 
thawed according to the manufacturer’s protocol as follows: For each vial containing 4×106 
cardiomyocytes, 2×T75 tissue culture flasks were used. The tissue culture flasks were 
coated with fibronectin (Sigma-Aldrich) at 10 μg/mL before plating cells. Cor.4U 
cardiomyocytes were thawed in manufacturer-provided thawing medium and allowed to 
attach for 3 hours, and then the medium was changed to manufacturer culture medium. 
Ciprofloxacin (provided by the manufacturer) was supplemented at 2 μg/mL throughout 
culture to reduce risk of bacterial contamination. The cells were cultured in T75 flasks for 
2 days to allow recovery before re-plating as monolayers. 
For cell monolayers, 35 mm cell culture dishes were coated with fibronectin, and 
the growth area was restricted to a 10 mm diameter circle with PDMS stencil as described 
in Fig. 2.9A. Cor.4U cardiomyocytes in T75 flasks were dissociated with 0.05% trypsin 
(ThermoFisher) into single cells, counted and plated at 1.6×105 cells/cm2. Cells were 
cultured as monolayers for 8-9 days before optical mapping experiments, using the method 
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described in Chapters 2 and 3. Due to the limit in the number of cells available for the 
CiPA phase 1 study, each drug was tested in only one hiPSC-CM monolayer.  
Table 4.1 List of drugs tested and their respective concentrations. 
 













IKr 0.003 0.01 0.03 0.1 
Nifedipine ICaL 0.01 0.03 0.1 0.3 
Mexiletine 
hydrochloride 
INa 1 3 10 30 






IKr, IKs, Ito 
















3 10 30 100 
 
As part of the CiPA phase 1 study, all tested drugs were obtained from the CiPA 
group coordinating experiments among different participating sites. The drug 
concentrations tested are listed in Table 4.1. A stock solution of each compound that was 
1000× the lowest concentration tested was prepared for each set of drug experiments, and 
different concentrations of drugs were tested serially by adding the necessary amount of 
stock drug solution to the chamber bath solution to achieve the desired test concentration. 
Between concentrations the monolayers were allowed 10 min for the drug effect to reach 
steady-state. Electrical pacing at 1000 ms cycle length was delivered through a pair of 
platinum electrodes and applied for at least 1 min before recordings of paced action 
potentials to ensure action potential steady-state.  
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Data analysis, including pixel inclusion, action potential parameter measurement 
and variability calculation were performed as described in Chapters 2 and 3. 
4.2.2 Single cell computational simulation of action potential variability 
The computational model of the hiPSC-derived cardiomyocyte by Paci et. al (Paci 
et al., 2013) was implemented in MATLAB based on the mathematical equations provided 
in the supplemental information of the original publication, and is referred to as the baseline 
model. Except for model validation, the ventricular phenotype described in Paci et. al was 
used for all simulations. Population heterogeneity was simulated by introducing variability 
to 14 conductances associated with ion currents in the baseline model (summarized in 
Table 4.1). For a single cell in the population, each of the 14 conductances was scaled by 
a random variable drawn from a uniform distribution. This process was repeated in a 
population of 1×104 independent cardiomyocytes. The range of the uniform distribution 
from which the scaling factors were drawn is denoted as the level of variability of the cell 
population. For 1% variability, the scaling factors were between 0.99 and 1.01; likewise, 
for 10% variability the scaling factors were between 0.90 and 1.10. 
Electrical pacing was simulated by injecting current into the simulated cells at 550 
pA for a duration of 5 ms. The steady-state action potential was obtained by simulating 100 
action potentials paced at 1000 ms cycle length and then taking the last action potential in 
the series. Ion channel blockade was simulated by scaling the conductance with another 
linear factor denoting the level of blockade (for example, 0.5 for 50% blockade). The new 
steady-state action potential was then obtained by simulating another 100 action potentials 
paced at 1000 ms cycle length and taking the last action potential in the series. Action 
potential parameters (APD30, APD80 and variability measurement IQR-APD80) were 
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calculated using the same method used for experimentally obtained action potentials as 
described in Chapter 2. 




INa gNa Maximum conductance of the fast Na
+ current 
Ito gto Maximum conductance of transient outward K
+ current 
IK1 gK1 Maximum conductance of inward rectifier current 
INaK PNaK Maximum conductance of sodium potassium pump 
INaCa KNaCa Maximum conductance of sodium calcium exchanger 
Iup Vmaxup Maximum current of Ca
2+ uptake by SR 
ICaL gCaL Maximum conductance of L-type calcium current 
IKr gKr Maximum conductance of rapid delayed rectifier current 
IKs gKs Maximum conductance of slow delayed rectifier current 
If gf Maximum conductance of funny current 
Irel arel, brel, crel Maximum current of Ca
2+ release by ryanodine receptors 
IpCa gpCa Maximum conductance of sarcolemmal Ca
2+ pump current 
 
4.2.3 Computational monolayer simulation of action potential variability 
The monolayer simulation was performed by Joseph Yu in collaboration with Dr. 
Natalia Trayanova’s lab. For these simulations, the ventricular-like hiPSC-CM model 
described by Paci et al (Paci et al., 2013) was used as the baseline model to create a 
heterogeneous population of single cells. Different levels of electrophysiological 
variability were introduced to the individual cells as described in 4.2.2. In ion channel 
blockade experiments, the effect of the channel blocker was also simulated as described in 
4.2.2. The steady state condition of individual cells was achieved by pacing them at 1000 
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ms cycle length for 50 beats. The cells were then incorporated in a monolayer model 
containing 100×100 cells that represents a 1 cm × 1 cm square area, with each cell 
occupying a volume of 100 μm × 100 μm × 100 μm. The dimension of the simulated 
monolayer is similar to that of the monolayers studied in the optical mapping experiments. 
Electrical coupling was simulated by an isotropic intercellular conductance of 0.4 μS/mm. 
Electrical pacing was applied at 1000 ms cycle length at a strength of 60 μA/cm3 and a 
duration of 2 ms. It was delivered either to all cells simultaneously, effectively stimulating 
them all at the same time, or along one edge of the monolayer, simulating a line electrode 
and initiating a line of propagating action potentials. The monolayer model was solved 
using the Cardiac Arrhythmias Research Package (CARP) as previously described 
(Vigmond et al., 2003; 2008) for 10 beats at 1000 ms cycle lengths, and the last beat was 
used for analysis. 
 
Figure 4.1 Schematic of a monolayer with defined electrophysiological heterogeneity. 
To create the monolayer, cells with homogeneous electrophysiology (left) are modified 
through computational methods to generate variability in their ion currents, which is 
reflected in their APD (middle). This population of heterogeneous cellular 
electrophysiology is then organized in a 2D monolayer (right) for drug response testing. 
Taking advantage of the flexibility in computational simulations, monolayers with 
defined patterns of heterogeneity can be easily established. Fig. 4.1 shows the schematic 
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of creating a such a monolayer from the population of individual cells with heterogeneous 
action potentials. In the example of Fig. 4.1, cells were coupled together and arranged in 
such a way to create a linear gradient in action potential durations along one dimension of 
the monolayer, so that cells with longer APDs are placed towards the top edge of the 
monolayer, while cells with shorter APDs are placed towards the bottom edge of the 
monolayer. By using this model and stimulating action potential propagation in the 
perpendicular direction, a spatial gradient in repolarization can be created in a controlled 
manner, and its response to drug can then be tested. In addition to arranging cells to create 
a linear APD gradient, single cells were also placed in two other different ways: 1) random 
placement, where cells were randomly placed into the monolayer; 2) concentric placement, 
where cells were sorted by their single cell steady-state APD, and those with shorter APD 
were placed in the center of the monolayer while those with longer APD were placed 
towards the edges of the monolayer.  
4.3 Results 
4.3.1 Monolayer response to selective ion channel blockers 
The experiments for the CiPA phase 1 study were conducted with the assistance 
from Dr. Venkatesh Hariharan. The responses of Cor.4U cardiomyocyte monolayers to 
selective ion channel blockers are summarized in Fig. 4.2.  
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Figure 4.2 Cor.4U monolayer response to selective ion channel blockers. (A) E-4031, 
an IKr blocker. (B) Nifedipine, an ICaL blocker. (C) Mexiletine, an INa blocker. (D) JNJ303, 
an IKs blocker. For each drug: a. average action potential of the entire monolayer. b. APD80 
histograms of action potentials from multiple sites (as indicated by the numbers next to the 
histograms) across the monolayer. Drug concentration is indicated by the same color in (a). 
c. IQR-APD80 for the monolayer at different drug concentrations. d. average conduction 
velocity for the monolayer at different drug concentrations. 
E-4031 
E-4031 is a selective blocker of the rapid component of the delayed rectifier 
potassium current (IKr), a repolarizing current. It was applied to the monolayer at a 
concentration of 0.003-0.1 μM. At 0.1 μM, the monolayer lost capture to external pacing 
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at 1000 ms cycle length. At all other concentrations, E-4031 produced a concentration-
dependent prolongation in action potential (Fig. 4.2A-a). The prolongation was mostly 
during the rapid repolarization phase, resulting a more triangular action potential with drug. 
APD80 histograms widened with E-4031, especially at higher concentrations (Fig. 4.2A-b). 
indicating an increase in action potential variability, which is also reflected in increased 
IQR-APD80 (Fig. 4.2A-c). The conduction velocity was not affected by E-4031 (Fig. 4.2A-
d). 
Nifedipine 
Nifedipine is a selective blocker of the L-type calcium current (ICaL), a depolarizing 
current. It was applied at 0.01-0.3 μM. The monolayer became quiescent at 0.3 μM 
concentration. At all other concentrations, nifedipine shortened the action potential in a 
concentration-dependent manner (Fig. 4.2B-a). Nifedipine did not change action potential 
variability in the monolayer, as shown in the APD80 histograms and IQR-APD80 
measurements(Fig. 4.2B-b, c). Conduction velocity was not affected by nifedipine (Fig. 
4.2B-d). 
Mexiletine 
Mexiletine is a selective blocker of the voltage-gated sodium current (INa), the 
depolarizing current that initiates the action potential. At concentrations higher than 300  
μM it can also inhibit Ca2+ and Na+/K+ pump currents (Honerjäger et al., 1986). The 
concentration tested was much lower at 1-30 μM. The monolayer maintained capture at 
1000 ms cycle length pacing for all concentrations tested, and the action potentials 
lengthened in a concentration-dependent manner (Fig. 4.2C-a). Mexiletine also increased 
action potential variability, as shown in the APD80 histograms and IQR-APD80 (Fig. 4.2C-
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b,c). Conduction velocity was greatly slowed by mexiletine, consistent with its INa blocking 
effect (Fig. 4.2C-d). 
JNJ303 
JNJ303 is a potent blocker of the slow component of the delayed rectifier potassium 
current (IKs), another repolarizing current during the cardiac action potential. It was applied 
at concentrations of 0.01-0.3 μM. Cor.4U monolayers maintained captured at 1000 ms 
cycle length external pacing at all concentrations. However, JNJ303 did not affect the 
action potential or its variability (Fig. 4.2D-a-c), or conduction velocity (Fig. 4.2D-d) at 
the concentrations tested. 
4.3.2 Monolayer response to ion channel blockers with mixed or off-target effects  
The responses of Cor.4U cardiomyocyte monolayers to ion channel blockers with 
mixed or off-target effects are summarized in Fig. 4.3. 
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Figure 4.3 Cor.4U monolayer response to cardioactive drugs with mixed ion channel 
blocking effect. (A) Flecainide, a class Ic antiarrhythmia drug. (B) Moxifloxacin, an 
antibacterial agent. (C) Quinidine, a class Ia antiarrhythmia drug. (D) Ranolazine, an anti-
angina drug. For each drug: a. average action potential of the entire monolayer. b. APD80 
histograms of action potentials from multiple sites (as indicated by the numbers next to the 
histograms) across the monolayer. Drug concentration is indicated by the same color in (a). 
c. average conduction velocity for the monolayer at different drug concentrations.  
Flecainide 
Flecainide is a class Ic antiarrhythmic drug, that mainly blocks INa and has slow 
unbinding dynamics but has also been shown to interact with the repolarizing currents IKr, 
IKs and Ito (Slawsky and Castle, 1994). Flecainide was applied at concentrations of 0.1-3 
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μM. The monolayer maintained capture at all concentrations tested, and the action potential 
was prolonged in a concentration-dependent manner (Fig. 4.3A-a) in both the plateau and 
repolarization phases, giving the action potentials a slightly more triangular morphology at 
high concentrations. Flecainide led to an increase in action potential variability at high 
concentration, as shown in the much wider spread of APD80 (Fig. 4.3 A-b) as well as 
increased IQR-APD80 (Fig. 4.3 A-c). Conduction velocity was also decreased by this drug 
at high concentration (Fig. 4.3 A-d), consistent with its INa blocking effect. 
Quinidine 
Quinidine is a class Ia antiarrhythmic agent that primarily blocks INa but also 
interacts with IKr and ICaL (Nenov et al., 1998). Quinidine was tested at concentrations of 
0.3-10 μM. At 3 μM, the monolayer could be pace-captured only during every other beat 
at 1000 ms cycle length pacing (2:1 capture), while at 10 μM it failed to be captured 
completely. Action potentials were greatly prolonged by quinidine in a concentration-
dependent manner (Fig. 4.3B-a), and become very triangular in morphology. Quinidine 
slightly increased action potential variability as shown in APD80 histogram and measured 
by IQR-APD80 (Fig. 4.3B-b,c). Conduction velocity was also decreased by quinidine, as 
expected for its INa blockade effect (Fig. 4.3B-d). 
Ranolazine 
Ranolazine is an anti-angina drug that primarily blocks the late inward sodium 
current (INaL). It has also been shown to interact with IKr (Antzelevitch et al., 2004). The 
concentration range tested for ranolazine was 1-30 μM. At 10 and 30 μM, the monolayer 
failed to maintain 1:1 capture at 1000 ms cycle length external pacing. Action potentials 
were prolonged in a concentration-dependent manner, with prolongation occurring 
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throughout repolarization. The action potentials also became more triangular with 
ranolazine (Fig. 4.3C-a). At 1 and 3 μM while the monolayer kept 1:1 capture, the action 
potential variability was slightly increased (Fig. 4.3C-b,c), while conduction velocity was 
not affected (Fig. 4.3C-d). 
Moxifloxacin 
Moxifloxacin is a fluoroquinolone antibacterial agent. However, there is evidence 
that it also has off-target blockade effect on IKr (Bischoff et al., 2000; Kang et al., 2001).  
It was tested at concentrations of 3-100 μM. Moxifloxacin prolonged action potential in a 
concentration-dependent manner, mainly during the plateau phase and did not lead to a 
more triangulated AP morphology, which is in contrast to the observation with selective 
IKr blocker E-4031 (Fig. 4.3D-a). Action potential variability was markedly increased by 
this drug, and there was a separation of the APD80 histogram into two peaks, possibly 
suggesting a differential response of two populations of cells to the drug (Fig. 4.3D-b,c). 
Conduction velocity was not affected by moxifloxacin (Fig 4.3D-d). 
4.3.3 Single cell simulation of action potential variability 
Numerical simulations using the MATLAB implementation of the 2013 Paci model 
of hiPSC-derived cardiomyocytes were compared against published simulation data of 
spontaneous activities and confirmed that the MATLAB implementation generated results 
identical to those published by Paci et al for both ventricular-like and atrial-like baseline 
models. Electrical stimulation was able to pace-capture both models, and electrically paced 
action potentials were obtained at 1000 ms cycle length, and are shown in Fig. 4.4. The 
action potentials maintained their phenotypic shapes, such as a more prominent plateau 
phase and longer duration for ventricular-like cells, and a more triangular, shorter duration 
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action potential for atrial-like cells. The model was paced for 100 beats to reach steady 
state, which was confirmed by minimal beat-to-beat differences in ion currents as well as 
intracellular ion concentration transients. The ventricular-like model was used in 
subsequent simulations. 
 
Figure 4.4 Steady state action potential, ion currents, and intracellular ion 
concentrations of hiPSC-CM computational model. (A) Ventricular-like hiPSC-CM, 
(B) Atrial-like hiPSC-CM. External pacing was applied at 1000 ms cycle length.  
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When variability was introduced to the conductance of each ion current in the 
baseline model, it led to deviations of steady-state action potentials from the baseline model 
as expected. Visually, this is demonstrated in Fig. 4.5A, where action potentials simulated 
from a population of 10000 independent cardiomyocytes with 10% variability in all 
conductances are shown. The spread in action potential morphology indicates the action 
potential variability, and can be quantified by IQR-APD80 similar to the experimental data. 
The corresponding histogram is shown in Fig. 4.5B, where a Gaussian-like distribution 
with a single peak was observed, which is expected since only the ventricular-like 
phenotype model was used to derive the heterogeneous population. Despite the variability 
introduced into the simulated cell population, the average action potential characteristics 
were largely unaffected, as indicated by the virtually unchanged average APD80 for the 4 
different populations of simulated cells with 1%, 2%, 5% or 10% variability (Fig. 4.5C). 
However, the spread in APD80 increased with increased variability, as shown by the 




Figure 4.5 Single cell simulation of action potential variability. (A) Steady-state 
simulated action potentials of a population of independent cardiomyocytes with 10% 
variability paced at 1000 ms cycle length. (B) APD80 histogram of the population of 
simulated cardiomyocytes in A. (C) Average APD80 of 4 different populations of simulated 
cardiomyocytes with 1%, 2%, 5% or 10% variability. (D) IQR-APD80 of the 4 different 
populations of simulated cardiomyocytes in C. (E) Baseline APD80 and scale factors for all 
14 conductances. Each row represents the scale factors for an individual ion current 
conductance, and each column corresponds to a single simulated cell. The columns were 
sorted by their baseline APD80 values to visually show correlation between baseline APD80 
and multipliers of conductances. (F) Baseline APD80 dependency on scaling factors for 
three ion currents, demonstrating different types of correlations: a. IKr, showing negative 
correlation. b. ICaL, showing positive correlation. c. IKs, showing lack of correlation.  
The relative importance of each ion conductance in determining the baseline APD80 
values is demonstrated in Fig. 4.5E, where each column represents the scale factors used 
for an individual cell in the heterogeneous population of simulated cells, color-coded by 
their values, and each row represents the scale factors used for an individual ion current 
across all 10000 cells. By sorting the columns in the ascending order of the baseline APD80 
of corresponding cells, the correlation (or lack of correlation) between baseline APD80 and 
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each scale factor can be visualized. Among all conductances, it became apparent that gCaL 
and gKr are the predominant factors influencing baseline APD80, since cells with reduced 
gCaL (as indicated by blue in the gCaL row) and with enhanced gKr (as indicated by yellow 
in the gKr row) are those have shorter baseline APD80, and vice versa. This is also indicated 
by the negative correlation between baseline APD80 and IKr scale factor (Fig. 4.5F-a) and 
the positive correlation between baseline APD80 and ICaL scale factor (Fig. 4.5F-b). On the 
other hand, other scale factors did not impact APD80 as strongly as for IKr or ICaL, as 
indicated by the intermixed pattern of scale factors when sorted by baseline APD80 (Fig. 
4.5E), and, in the example of IKs, the lack of correlation between baseline APD80 and its 
scale factor (Fig. 4.5F-c). The R-squared values for linear regression models between 
baseline APD80 and gKr, gCaL and gKs were 0.31, 0.51 and 0.0004, respectively, 
consistent with the observation of strong correlations with gKr or gCaL, and a weak 
correlation with gKs. 
The effect of ion channel blockade on population heterogeneity was then 
investigated for ICaL and IKr, because of their high correlation with baseline APD80. Channel 
blockade was simulated by reducing the maximum conductances for ICaL or IKr by 50% 
respectively, in a population with 10% variability across all ion channels. Overall, ICaL 
blockade led to shortening of the action potentials (Fig. 4.6A), while IKr blockade led to 
prolongation of the action potentials (Fig. 4.6B). At a population level, ICaL blockade 
caused a left shift in the APD80 histogram (Fig. 4.6C, black to blue) that is consistent with 
the shortening of action potentials, but did not affect the spread of the histogram. On the 
contrary, IKr blockade led to a wider spread in the APD80 histogram in addition to the 
overall right shift (Fig. 4.6C, black to red). The response in population variability can be 
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measured by IQR-APD80 as shown in Fig. 4.6D, where little change was observed with 
ICaL blockade, and a dramatic increase was observed with IKr blockade. The mechanism of 
increased APD80 variability with IKr blockade was further investigated. Fig. 4.6E shows the 
dependency of ΔAPD80 on baseline APD80. In general, a positive correlation was observed, 
where cells with longer baseline APD80 responded to IKr blockade more strongly, as 
indicated by the larger ΔAPD80. However, there was also notable variability in ΔAPD80 
even for cells with similar baseline APD80, as evident by the large vertical spread in the 
scatter plot. Combined, the positive dependency on baseline APD80 and the high variability 
for cells with similar baseline APD80 led to the increase in IQR-APD80 with IKr blockade. 
Further, the correlation of ΔAPD80 to ion current scale factors is shown in Fig. 4.6F in a 
manner similar to Fig. 4.5E, except the columns (representing each cell) are now sorted by 
ΔAPD80. Interestingly, there is a strong correlation between ΔAPD80 and PNaK, the 
maximum conductance for the Na+-K+ pump, while no correlation was apparent between 
ΔAPD80 and other ion current scale factors. This positive correlation is also demonstrated 
in the ΔAPD80 dependency on PNaK scale factor (Fig. 4.6G), where cells with higher 
PNaK values had longer ΔAPD80 when IKr was blocked by 50%. At the same time, ΔAPD80 
variability was also greater for cells with larger PNaK scale factors, as indicated by the 
wider vertical spread in the scatter plot. On the contrary, ΔAPD80 did not have a strong 
correlation with the IKr scale factor with 50% IKr blockade (Fig. 4.6H). The R-squared 
values for linear regression models between ΔAPD80 and PNaK and gKr were 0.65 and 
0.044, respectively, consistent with the observation of strong correlations with PNaK, and 
a weak correlation with gKs. 
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Figure 4.6 Ion channel blockade in heterogeneous population of independent cells. 
(A,B) Responses of a population of 10000 simulated hiPSC-CM populations with 10% 
variability and either 50% ICaL (A), or IKr (B) blockade. (C) Histograms of APD80 at 
baseline (black), 50% ICaL blockade (blue) or 50% IKr blockade (red) for the cell population 
in A, B. (D) IQR-APD80 changes with 50% ICaL or IKr blockade. (E) ΔAPD80 dependency 
on baseline APD80 at 50% IKr blockade of the population shown in B. (F) ΔAPD80 
dependency on scale factors for ion currents. Each row represents the scale factors for an 
individual ion current conductance, and each column corresponds to a single simulated 
cell. The columns were sorted by their responses to 50% IKr blockade, as measured by 
ΔAPD80. (G) ΔAPD80 dependency on PNaK scale factor, showing a positive correlation. 
(H) ΔAPD80 dependency on IKr scale factor, showing a general lack of correlation. 
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4.3.4 Monolayer simulation of action potential variability 
To further investigate the effect of electrophysiological variability on drug response 
in a syncytial context, a monolayer model was constructed with electrically coupled cells. 
For this section, 10% variability in ion channel conductance was used. Electrical coupling 
is expected to affect the observed action potential variability by allowing passive current 
to flow across neighboring cardiomyocytes and electronically averaging out differences in 
transmembrane voltage. When there was no electrical coupling among cells, action 
potentials recorded from individual sites within the simulated monolayer reflect their 
independent steady-state conditions, regardless of how they were distributed across the 
monolayer. An example of random distribution is shown in Fig. 4.7A. The intermixed 
pattern in the spatial APD80 map reflects the random distribution of the cells. The APD80 
distribution shows a single Gaussian-like distribution representing the variability within 
this cell population. Electrical coupling nearly eliminated the action potential variability in 
this randomly distributed monolayer, as shown in Fig. 4.7B. The APD80 histogram became 
very narrow, and the action potentials were essentially identical across the monolayer. 
However, if cells with similar electrophysiological properties were allowed to group 
together, either radially (Fig. 4.7C), or linearly (Fig. 4.7D), the action potential variability 
was only slightly reduced by electrical coupling. 
 117 
 
Figure 4.7 APD80 in cell monolayer simulations with electrical coupling. For each 
panel, top map shows APD80 across the monolayer, and bottom histogram shows APD80 
distribution within the monolayer. (A) No electrical coupling among cells. (B-D) Electrical 
coupling was introduced across the monolayer. (B) Cells were randomly placed across the 
monolayer. (C) Cells were placed in the monolayer so that shorter APD ones are towards 
the center, while longer APD ones are towards the outside of monolayer. (D) Cells were 
placed in the monolayer so that shorter APD ones are towards the bottom edge of the 
monolayer while longer APD ones towards the top edge of the monolayer. 
The monolayer with linear APD80 gradient as shown in Fig. 4.7D was then used to 
study the effect of IKr blockade on action potential variability and repolarization 
heterogeneity (Fig. 4.8). For this simulation, line pacing was applied on the left edge of the 
monolayer, so that a propagating action potential wave was initiated perpendicular to the 
APD80 gradient from left to right. Overall, 50% IKr blockade produced a prolongation in 
action potential, as shown by the right-shift of the APD80 histogram in red compared to the 
histogram in black in Fig. 4.8A. The action potential variability was also increased by the 
IKr blockade, indicated by the increased spread in APD80 histogram and the increased IQR-
APD80 shown in Fig. 4.8B. The spatial variability in the APD80 is shown in Fig. 4.8C for 
baseline (a) and for 50% IKr blockade (b) conditions. With average APD80 subtracted across 
the entire monolayer for each case, these spatial APD80 variation maps demonstrate how 
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APD80 values deviate from the average. For both baseline and IKr blockade conditions, 
APD80 variation roughly followed a linear pattern, with cells towards the top edge of the 
monolayer having longer APD80 while cells towards the bottom row of the monolayer 
having shorter APD80. In addition, IKr blockade increased the variation in APD80, as 
indicated by the deeper red towards the top of monolayer, and the deeper blue towards the 
bottom of the monolayer. This is consistent with the increased spread in the overall APD80 
histogram and increased IQR-APD80. To investigate how increased APD80 variability 
affects its spatial gradient, the APD80 gradient was quantified along the direction of the line 
of pacing as shown in Fig. 4.8D. When APD80 was measured from cells at the same 
distance from the line of pacing (for example, along the dashed line in Fig. 4.8C) and 
plotted against distance from the bottom of the monolayer, the resulting scatter plot roughly 
follows a linear pattern (red dots in Fig. 4.8D). This linear pattern is reflective of the linear 
gradient used to construct the monolayer. When a line is fitted to the APD80 values, the 
slope of the line is a measurement of the APD80 gradient in the direction of the dashed line 
in Fig. 4.8C, which is parallel to the line of pacing. This measurement was repeated for 
different distances from the line pacing (noted by d in Fig. 4.8C-b) to calculate the APD80 
gradient across the entire monolayer, which is shown in Fig. 4.8 E to be greater under 
conditions of 50% IKr blockade. Thus, the increased APD80 variation resulting from IKr 
blockade led to an increased spatial gradient in APD80. 
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Figure 4.8 APD80 response to IKr blockade in simulated monolayer with defined linear 
variability. (A) APD80 histogram at baseline (black) or with 50% IKr blockade (red). (B) 
IQR-APD80 of the monolayer, showing an increase in action potential variability with IKr 
blockade. (C) APD80 variation map of this simulated monolayer at baseline (a) or with IKr 
blockade (b). The average APD80 was subtracted across the monolayer for each condition 
to highlight the variability. Orange/red region indicates cells with APD80 longer than 
average, and cyan/blue region indicates cells with APD80 shorter than average. Solid line 
indicates applied line pacing, and dashed line shows the direction along which the spatial 
gradient of APD80 was calculated. (D) Example of APD80 gradient calculation. Red dots 
indicate APD80 values measured along the dashed line in C-b, which is in parallel with the 
line of pacing. Solid line indicates linear fit of the APD80 data. The slope of the fitted line 
is the APD80 gradient along the direction parallel to the line of pacing. (E) APD80 gradient 
measured at different distances from the line of pacing, in the direction parallel to the line 
of pacing. Blue line indicates baseline condition, red line indicates 50% IKr blockade 
condition. 
Next, repolarization heterogeneity was quantified as the local gradient of 
repolarization time, as shown in Fig. 4.9. The heterogeneity in action potentials led to a 
slight tilt in the activation wavefront, with conduction velocity being slightly faster on the 
bottom of monolayer where the action potential was shorter than on the top of monolayer 
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where the action potential was longer. (Fig. 4.9A-a). This was a result of the longer 
diastolic interval on the bottom than on the top, which gives more time for INa to recover 
and provide more excitatory current. This heterogeneity in conduction became greater with 
50% IKr blockade, as shown in the more prominent tilt in the activation wavefronts (Fig. 
4.9B-a). The repolarization time, which is the sum of activation time and APD80, is shown 
in Fig. 4.9A-b for baseline and Fig. 4.9B-b for 50% IKr blockade condition. The isochone 
lines for repolarization time were also tilted, as a combined effect of tilted activation and 
heterogeneous APD80. The spatial gradient of repolarization time was then calculated for 
each cell within the monolayer, which is a measurement of the difference in repolarization 
times in the local vicinity of each cell. The magnitude and direction of the local gradients 
are shown in Fig. 4.9A-c and Fig. 4.9B-c, and the histograms of the magnitude are shown 
in Fig. 4.9A-d and Fig. 4.9B-d. IKr blockade led to an increase in the repolarization time 
gradient across the monolayer, as indicated by the deeper red across the monolayer, as well 
as the right-shifted histogram. The increased repolarization time gradient indicates an 




Figure 4.9 Repolarization time gradient response to IKr blockade. (A) Baseline and (B) 
50% IKr blockade. In each condition: a. activation time across the monolayer. b. 
repolarization time across the monolayer. In a and b, isochrones have 100 ms spacing. c. 
local gradient of repolarization time calculated at the location of each cell in the simulated 
monolayer. Color map shows the magnitude of the gradient, and quiver plot shows the 
direction of the gradient. d. histogram of local repolarization time. 
The propagating action potential wave also creates a heterogeneity in 
transmembrane potential (Vm) across the monolayer during repolarization, and the local 
gradient can be calculated for individual cells as shown in Fig. 4.10A-a. The quiver plot 
indicates the magnitudes and the directions of the local Vm gradients. For each cell within 
the monolayer, the Vm gradient was calculated for each time point during a propagating 
action potential wave, and the magnitude of the Vm gradient is shown in Fig. 4.10A-b for 
one cell as an example. There are two distinct peaks in the Vm gradient trace. The first, 
larger peak corresponds to the depolarizing wave front as it propagates across the cell. The 
second, smaller peak corresponds to the repolarizing wave tail as it propagates across the 
cell. The maximum Vm gradient during repolarization governs the intercellular current that 
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can pass during action potential repolarization and generate an ectopic beat, and is therefore 
a potential proarrhythmia index. Fig. 4.10B and Fig. 4.10C show the maximum Vm 
gradients calculated across the simulated monolayer at baseline and at 50% IKr blockade 
conditions, respectively. IKr blockade led to an increase in the maximum Vm gradient 
throughout the monolayer, as indicated by the deeper red regions found in the spatial map 
(Fig. 4.10B-a,C-a) and right-shift found in the histograms (Fig. 4.10B-b,C-b) for the 
blockade condition. 
 
Figure 4.10 Maximum Vm gradient during repolarization. (A) Calculation of Vm 
gradient of a propagating action potential wave. a. snapshot of Vm across the monolayer 
during a propagating action potential. The wave front has just left the right edge of the 
monolayer. Quivers shows local Vm gradients and their directions. b. magnitude of Vm 
gradient calculated at different time points of a propagating action potential wave. Arrow 
indicate maximum repolarization Vm gradient. (B) Maximum repolarization Vm gradient 
during baseline and (C) 50% IKr blockade. For B and C: a. map of maximum Vm gradient 
measured during repolarization for each cell within the monolayer. b. histograms of 
maximum Vm gradient measured during repolarization.   
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4.4 Discussion 
The key to a good in vitro model for drug-induced proarrhythmia is determining 
the set of biomarkers that best predicts drug effects. Electrophysiological properties 
measured by optical mapping of cm-sized monolayers of hiPSC-CMs provide the basis for 
establishing a suitable set of biomarkers. Among these properties, some are similar to those 
obtained by patch clamp or MEAs, such as action potential duration and EAD occurrence; 
some are tissue-level properties that cannot be measured with single cells or small clusters, 
such as conduction velocity; and yet others are population properties that are revealed by 
the monolayers used in the current study, such as variabilities. 
An in vitro platform for testing drug-induced proarrhythmia should be validated by 
showing appropriate responses to cardioactive drugs with relatively selective known 
effects. Previous studies have shown that hiPSC-CMs are promising in this aspect (Blinova 
et al., 2017; Dick et al., 2010; Lu et al., 2017), but the results can be confounded by the 
immaturity and heterogeneity of the cells (Sinnecker et al., 2014). The 4 selective ion 
channel blockers (E-4031, nifedipine, nexiletine and JNJ303) as provided by the CiPA 
initiative are designed to test if Axiogenesis Cor.4U cardiomyocyte monolayers respond to 
specific channel blockers in the expected ways. Of the 4 drugs, E-4031 is generally 
considered selective to IKr, without affecting INa or ICa in concentrations up to 10 μM 
(Wettwer et al., 1991). Nifedipine is an L-type calcium channel blocker of the 
dihydropyridine family and also generally considered to be selective. It can, however, 
block the T-type calcium current at concentrations above 1 μM (McDonald et al., 1994). 
Mexiletine is an INa blocker, although at concentrations higher than 300 μM it can also 
inhibit Ca2+ and Na+/K+ pump current (Honerjäger et al., 1986). JNJ303 is a potent IKs 
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blocker, with an IC50 for IKs at 0.064 μM and for other major cardiac ion channels much 
higher than 1 μM (Towart et al., 2009). The concentrations tested for each drug were much 
lower than the concentrations reported for their respective non-specific blockade effects, 
and therefore in theory these 4 drugs should serve as specific ion channel blockers. The 
responses of Axiogenesis Cor.4U cardiomyocyte monolayers generally reflected the 
expected responses based on drug mechanism: prolongation of action potential with IKr 
blockade with E-4031, and shortening of action potential with ICaL blockade with 
nifedipine. Qualitatively, Cor.4U cardiomyocyte monolayers were more sensitive to E-
4031 compared to guinea pig papillary muscles as previously suggested (Wettwer et al., 
1991) and as indicated by a more prominent prolongation in APD. This increased 
sensitivity could arise if hiPSC-CMs have reduced repolarization, as previously 
demonstrated in a simulation study (Paci et al., 2015). The INa blocker, mexiletine, also 
prolonged the action potential but to a much lesser degree than E-4031. The prolongation 
in repolarization was also observed previously using hPSC-CMs and MEAs, but in those 
studies it could be a secondary effect of the slowing of spontaneous rate with mexiletine, 
as when beating rate was corrected for, no significant changes in the corrected FPD (FPDc) 
were observed (Clements and Thomas, 2014; Harris et al., 2013). In this study, pacing rate 
was fixed at 1000ms cycle length and therefore no correction for APD was necessary. The 
prolongation in APD80 observed here could be an effect secondary to the reduced 
excitability because of INa block. Mexiletine is also an example of the utility of the 
monolayer model, in that the effect of INa blockade is faithfully captured by the slowing in 
conduction velocity. On the other hand, IKs blocker JNJ303 did not produce any meaningful 
response in Cor.4U monolayers, suggesting either Cor.4U cardiomyocytes lack expression 
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of IKs, or IKs has a limited effect in determining APD in the Cor.4U cardiomyocyte 
monolayers, as was the case in rabbit ventricular muscle (Lengyel et al., 2001). The 
increased sensitivity to IKr blockade suggests reduced repolarization reserve in Cor.4U 
cardiomyocytes and therefore seems to support the former possibility. On the other hand, 
expression of IKs has been reported in hiPSC-CMs, and prolongation of action potentials 
(Jonsson et al., 2012; Peng et al., 2010) or field potential durations (Honda et al., 2011; 
Nozaki et al., 2014) was observed using a different IKs blocker, chromanol 293B. These 
different observations indicate further work to improve consistency in hiPSC-CM 
characteristics is still needed. 
The unique structure of the hERG protein makes it a likely target of unintentional 
binding to a wide range of drugs (Mitcheson and Perry, 2003), and also makes it a primary 
target for drug screening under current guidelines. The drugs with mixed or off-target 
channel blocking effects tested in this chapter (flecainide, quinidine, ranolazine and 
moxifloxacin) have all been shown to interact with hERG at concentrations relevant to the 
concentrations tested in the CiPA phase 1 study (Antzelevitch et al., 2004; Colatsky, 1982; 
Kang et al., 2001; Slawsky and Castle, 1994). In Cor.4U monolayers this IKr interaction 
was manifested as prolongation of the action potential. Further, flecainide and quinidine, 
the two INa blockers, also led to a reduction in conduction velocity across the monolayer in 
addition to the prolongation of APD. The moxifloxacin-induced increase in IQR-APD80 
and appearance of two peaks in the APD80 histogram is rather interesting, as this emerging 
separation of phenotypes was not observed with any other drugs, including those that 
increased IQR-APD80 (E-4031, mexiletine and flecainide). This could suggest that the IKr 
blocking effect associated with moxifloxacin is different from that of E-4031 (which 
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increased IQR-APD80 but did not lead to two peaks in the APD80 histogram), and that 
cellular heterogeneity in monolayer culture can still manifest different observed 
phenotypes under certain conditions. Overall, these observations demonstrate that the 
monolayer model can be a promising platform for the integrated evaluation of drugs that 
affect multiple aspects of cardiac electrophysiology. 
The heterogeneity in hiPSC-CM phenotypes can complicate the interpretation of 
drug response in these cells (Sinnecker et al., 2014), since drugs can have differential 
effects on the cardiomyocytes. In Chapter 2, I have shown that monolayer culture 
promoted a single phenotype in Cor.4U cardiomyocytes, despite the manufacturer’s 
specification of a mixed population (Kettenhofen et al., 2014). This provides a consistent 
baseline for drug response testing. Further, even within a single monolayer, the response 
to drug is evaluated at over 6000 recording sites simultaneously across the monolayer. The 
uniform response within individual monolayers to all compounds tested further 
demonstrated the similarity in electrophysiology of cells in monolayer culture. In addition, 
variability in monolayers is affected strongly by some drugs (E-4031, mexiletine, 
moxifloxacin and quinidine), slightly by other drugs (quinidine and ranolazine), and little 
by the remaining drugs (nifedipine and JNJ303). Drug-induced increase in heterogeneity 
can potentially be a biomarker for proarrhythmia, which can be accentuated further by 
experimental approximations of in vivo heterogeneity of the myocardium. One limitation 
to the monolayer approach, however, is that monolayer culture requires a larger number of 
cells compared to smaller clusters used with MEAs or single cells with patch clamp. In the 
CiPA phase 1 study, this limitation resulted in only one monolayer being tested for each 
drug. This limitation is partially compensated for by the large number of APs recorded 
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within each monolayer, as well as the high consistency in APs within and across 
monolayers. 
Simulations can provide insight on population properties. Both maximum 
conductance and gating parameters have been altered to model electrophysiological 
variability in cardiomyocyte models (Romero et al., 2009) and produced variation in APD 
as a result. Only scaling of conductance, and not changes in kinetics, was used for studies 
in this chapter to simulate biological variation in channel expression, and the result is 
consistent with the expectation of creating a heterogeneous population of action potentials. 
The computational APD80 histogram also shares qualitative similarity to that observed with 
monolayer mapping, resembling a single peak Gaussian-like distribution. One interesting 
finding in simulations of the single cell population is the increase in variability with 
blockade of IKr. The blockade of IKr was modeled by a reduction in its maximum 
conductance gKr by a factor of 50%, which simulates the blockade of the current-
conducting pore of the channel. Therefore, the blockade also reduces the variability in gKr 
by 50%. One may expect that this reduction in gKr would reduce the variability in IKr, 
which in turn should reduce overall action potential variability. However, the opposite 
result was observed in simulations, which showed that that prolongation of the action 
potential by IKr blockade also extended the duration of the plateau phase, which reflects the 
precise balance between inward and outward ion currents and is very sensitive to small 
changes in individual ion currents. Despite reduced variability in gKr, the action potential 
variability can increase because of the variability in other ion currents. A previous study 
using human and canine ventricular myocytes demonstrated that the response to IKr 
blockade is indeed affected by variability in ion currents to different extents (Sarkar and 
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Sobie, 2011). In the hiPSC-CM case shown in this chapter, the variability in INaK (an 
outward current that repolarizes Vm) turned out to be highly correlated to the response 
variability to IKr blockade, suggesting that INaK is an important reserve current during 
repolarization in this hiPSC-CM model. 
Computational models of electrically coupled monolayers of cardiomyocytes have 
the flexibility to create arbitrary distributions of heterogeneity. Different distributions of a 
heterogeneous population of cells in the presence of electrical coupling resulted in large 
differences in APD variability: electrical coupling nearly abolished variability if cells were 
randomly distributed, while this variability remained clearly visible if the cells were 
distributed in an organized manner, either radially or linearly. This observation suggests 
that an intermixed distribution of cells having heterogeneous electrophysiology is unlikely. 
Since synchronized electrical activity is capable of causing long term remodeling and 
maturation in hiPSC-CMs (Chan et al., 2013; Lieu et al., 2013), it could also reduce the 
differences in their electrophysiology. In either case, the observed variability is reduced 
compared to the uncoupled state. 
The asynchronous repolarization in human heart determines the morphology of the 
T wave in human ECG. A change in T wave morphology, which reflects a change in 
repolarization heterogeneity, has been linked to hERG blockade and proarrhythmic risk in 
human (Hanton, 2014; Vicente et al., 2015). The computational model of an hiPSC-CM 
monolayer with linear APD gradient described in this chapter provides an in silico platform 
to test this important proarrhythmia biomarker. Similar to observations in isolated hiPSC-
CM populations, IKr blockade also led to an increase in APD80 variability, which is 
manifested as an increase in the spatial gradient of APD80 in the monolayer model. At the 
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tissue level, the increased APD80 gradient by IKr blockade further increased the 
repolarization gradient in two ways: 1) increase of the repolarization time gradient (Fig. 
4.9) and 2) increase of the maximum Vm gradient during repolarization (Fig. 4.10). Both of 
these metrics of repolarization gradient are potentially proarrhythmic. The increased 
repolarization time gradient increases the heterogeneity in refractory state across the 
monolayer, which in turn affects excitability and can potentially lead to proarrhythmic 
unidirectional conduction block. The increased maximum Vm gradient during 
repolarization can increase the flow of intercellular current, which, when exceeding a 
certain threshold, will trigger ectopic activities such as EADs. Taken together, in a 
monolayer with defined heterogeneity, biomarkers such as repolarization gradient can be 
measured for assessing drug-induced proarrhythmia risk.  
In conclusion, a monolayer model using Cor.4U cardiomyocytes exhibited 
expected responses to cardioactive drugs. For drugs with mixed channel blocking effects, 
individual effects can be captured by separate electrophysiological properties. 
Computational simulations of heterogeneous populations of hiPSC-CMs demonstrated 
channel blockers can affect action potential variability, and in monolayer models with 
defined heterogeneity, the repolarization gradient provides another potential biomarker for 





Chapter 5  
Conclusions 
5.1 Summary of findings 
In my thesis, I investigated the utility of hPSC-CMs for in vitro cardiac 
electrophysiology studies. Population-based analysis of action potential variability was 
first investigated in an hEB model and then in a monolayer-based model. It was found that 
the monolayer model promotes similarity in the electrophysiology of hPSC-CMs, which 
provides a consistent baseline for downstream studies. Using this idea, an LQT2 disease 
model with hiPSC-CMs was then studied. Compared to single cell and small cluster 
models, the monolayer LQT2 model had prolonged action potentials and increased 
sensitivity to IKr blockade, but lacked EAD formation, although EADs were observed when 
the dimension of the monolayer was reduced. Conduction heterogeneity can also be 
induced either by premature pacing, or by creating local hypoxia in the monolayer model, 
for assessing disease-enhanced proarrhythmia. Lastly, the utility of the monolayer model 
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as a platform for testing drug-induced proarrhythmia was investigated. Monolayers of 
Cor.4U cardiomyocytes were shown to respond to cardioactive drugs with known effects 
in an expected manner, in both action potential measurements and conduction velocity 
properties. The monolayers also responded to mixed-effect drugs, with a combination of 
responses that are consistent with the drug interactions with ion channels. Computational 
models were used to simulate population variability in hiPSC-CMs, and the effect of IKr 
blockade was shown to increase, rather than decrease, the population variability. 
Monolayer simulations demonstrated electrical coupling will reduce variability observed 
in a heterogeneous population, but the effect was smaller when cells with similar properties 
were clustered together. They also demonstrated the utility of monolayers with defined 
heterogeneity in drug-induced proarrhythmia screening, where gradients in APD80 and 
repolarization time are candidates as proarrhythmia biomarkers. 
5.2 Future directions 
In Chapter 2, I demonstrated phenotype identification using an objective, 
waveform-based automated algorithm and compared the results with AP parameter-based 
methods. Advanced methods based on morphological changes have since been used to 
improve the algorithm (Gorospe et al., 2015). These objective algorithms can be used as a 
framework for more general studies to identify subgroups in large electrophysiological 
datasets, and how they evolve over time in a more dynamic setting. For example, during 
maturation, how does the action potential evolve to a more adult-like phenotype? Do 
ventricular-, atrial- and nodal-like phenotypes further diversify, or converge under different 
culture conditions? Drug testing using hiPSC-CMs can also benefit from automated 
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grouping algorithms. For example, can the responses in action potential to drugs be 
separated into groups, and how do these groups correspond to the mechanism of action of 
the drug? Can drug-induced proarrhythmia be stratified based on the grouping results of an 
automated algorithm? 
An immediate question following the observation of monolayer culture promoting 
a single electrophysiological phenotype is to further investigate its mechanism. In this 
thesis, I showed that acute treatments, including reduced electrical coupling and blockade 
of IKr, did not lead to phenotype separation. However, CBX treatment only reduces, rather 
than eliminates intercellular electrical coupling, which limits the interpretation of a single 
phenotype in monolayers. Nevertheless, experiments with acute treatments to reduce 
electrical cell-cell coupling cannot replace electrophysiological assays of truly independent 
(separated) hPSC-CMs, and it would be interesting to compare the electrophysiological 
phenotypes of single cells and monolayers of hPSC-CMs that are otherwise the same. 
Further, it would also be interesting to study the time course over which the different 
phenotypes of individual cells converge, which will shed light on the time course over 
which the electrophysiological phenotype of hPSC-CMs can change.  Environmental cues 
can then be applied to monolayer cultures to investigate their effect on the different 
phenotypes across the cell population to further investigate the mechanism of the emerging 
single phenotype. Instead of acute experiments with a voltage-sensitive dye that only 
allows assessment of short-term responses (typically less than one hour), genetically 
encoded voltage and/or calcium sensors can be used for multi-time point assessment and 
the analysis of the dynamics of electrophysiology variability. For example, do cell 
phenotypes still converge if electrical coupling is prevented or impaired during culture? 
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How does in-culture electrical stimulation affect the variability in monolayer models? 
Further, I have also shown evidence that physical dimension affects the electrophysiology 
of hPSC-CMs in an LQT2 diseased model. It is worth examining its mechanism by 
applying electrophysiological variability analysis to monolayers of different dimensions 
and geometry. Population analysis can also be applied to other tissue engineering models 
with large population of cells grown in different ways, such as with micro- or nano-
patterned substrates, decellularized extracellular matrix, 3-dimensional culture systems, 
etc. The manifestation of cellular variability in each of these models can give insight on 
cell-cell interactions and phenotype development within each model. 
Novel gene editing methods such as CRISPR/Cas9 can introduce precise mutations 
in cell lines, which can be used to generate isogenic cell lines with specified mutations and 
further strengthen in vitro disease modeling with hiPSCs. The study with LQT2-A422T 
cardiomyocytes will also benefit from gene editing methods. By correcting the point 
mutation in the diseased cell line and/or introducing the A422T mutation to a control cell 
line, the genotype-phenotype relationship can be better investigated. However, despite 
being an exciting new technology, CRISPR/Cas9 methods still have limitations when 
applied to specific mutations. For example, the availability of appropriate protospacer 
adjacent motif (PAM) sites around the hERG-A422T mutation site may not be ideal for 
the current Cas9 endonuclease-based system, and the low efficiency of homology directed 
repair (HDR) may post challenges in selecting successfully edited clones of hiPSCs. 
In Chapter 4, computational modeling demonstrated that ion channel blockers can 
affect the repolarization gradient in monolayers. How this relates to arrhythmogenisis  
requires further investigation. Repolarization gradients lead to differential excitability in 
 134 
the tissue, which creates a substrate for transient unidirectional conduction block. This can 
potentially lead to reentrant action potential propagation given the right stimulation 
conditions. Perhaps the change in repolarization gradient can be related to the time window 
during which the tissue is vulnerable to transient conduction block. This vulnerable 
window can be a quantifiable tissue-level biomarker for proarrhythmia risk. It is also worth 
exploring different predetermined APD gradients, as well as their effect on paced 
propagating action potentials. One approach, for example, would be to simulate the 
physiological gradient found across the ventricular wall, where data from canine 
experiments are available for differences in ion currents that are responsible for action 
potential heterogeneity, and data from human ventricle wedge preparations can provide a 
physiological baseline of APD heterogeneity. 
5.3 Conclusions 
My thesis work introduced a novel method to investigate the electrophysiology of 
hPSC-CMs by studying their tissue-level properties such as variability in large populations. 
It was inspired by the orchestrated activities in the human heart, and I have demonstrated 
that by allowing interactions among hPSC-CMs, similarities in their electrophysiology 
arise and a single phenotype emerges in a monolayer model. The utility of this monolayer 
model was then demonstrated in modeling LQT2 disease and studying drug response of 
hPSC-CMs, where tissue-level properties such as APD-dependency of drug responses and 
repolarization gradients were used to investigate disease- or drug- induced proarrhythmia. 
Future work is still needed to expand this framework to more disease models and extend 
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the library of drugs tested, and new tissue-level proarrhythmia biomarkers may be 
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